

BEST AVAILABLE COPY

REMARKS/ARGUMENTS

Amendments:

Claims 1-13 and 33 are pending. Claim 1 was amended to incorporate the recitations of claims 3, 4, 5, and 8. Support for the amendment to claim 1 is in original claims 1, 3, 4, 5 and 8.

Claims 3-5, 7-8 and 11-12 are canceled.

Claim 6 has been amended to depend on claim 2 - to correct a typographical error.

Claim 9 has been amended to depend on claim 1 instead of canceled claim 8.

Claim 10 has been amended to recite that the cooked composition is prepared according to the method of claim 1. Support for this amendment is in original claims 1 and 10.

Claim 33 has been amended to more clearly define the invention. Support for the amendment is in original claims 1, 3, 4, 5, 8 and 33. Further, claim 33 has been amended to correct a typographical error in numbering.

No new matter is added and the entry of the amendments is respectfully requested.

Claim Objections

The claims were objected to because two claims were mistakenly listed as claim 22. Applicants have canceled claims 12-32 to remove this inconsistency. Claim 33, erroneously listed as claim 32, has been amended to correct the typographical error. Since the pending claims, as amended, no longer contain duplicate numbers, withdrawal of this objection is respectfully requested.

Specification Objections:

The Examiner has objected to the specification as allegedly containing improper incorporations by reference (Office Action, page 2). The Examiner states that the instant application uses "omnibus" language and fails to teach with particularity where specific

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

information is to be found in each reference. *Id.* In support of this objection, the Examiner cited *Advanced Display Systems, Inc. v. Kent State Univ.*, 54 U.S.P.Q.2d 1673 (Fed. Cir. 2000) and also highlighted sections of *Advanced Display Systems, Inc.* that cited *In re Seversky*, 474 F.2d 671 (C.C.P.A. 1973) and *In re Lund*, 376 F.2d 982 (C.C.P.A. 1967). Applicants respectfully traverse this objection.

First, the *Seversky* and *Lund* cases are not applicable to the instant application. In the *Seversky* case, the Court of Customs and Patent Appeals held that the simple statement that a daughter application was a “continuation-in-part” of a parent application was insufficient to incorporate the parent application by reference. *Seversky*, 474 F.2d at 674. In the *Lund* case, the Court of Customs and Patent Appeals held that a single sentence in a pending application indicating that it was a “continuation-in-part” of an abandoned application was insufficient to incorporate the abandoned application by reference. *Lund*, 376 F.2d at 989. By contrast, the instant application contains clear language that the cited publications are “incorporated by reference” in the application. See, *inter alia*, page 10, lines 1-2 and page 28 last paragraph of the specification. Thus, *Seversky* and *Lund* are irrelevant to the instant case.

Second, Applicants have specifically described where the information is found in the incorporated references. According to *Advanced Display Systems*, the incorporated material must be described with sufficient particularity to “one reasonably skilled in the art.” *Advanced Display Systems*, 54 U.S.P.Q.2d at 1680. The instant specification discloses the first author, journal, volume, year, and page numbers for the incorporated publications. As an example, the paragraph spanning pages 4, lines 19-24 of the specification states:

FISH has historically been combined with classical staining methodologies in an attempt to correlate genetic abnormalities with cellular morphology [see e.g., Anastasi et al., Blood 77:2456-2462 (1991); Anastasi et al., Blood 79:1796-1801 (1992); Anastasi et al., Blood 81:1580-1585 (1993); van Lom et al., Blood 82:884-888 (1992); Wolman et al., Diagnostic Molecular Pathology 1(3): 192-199 (1992); Zitzelberger, Journal of Pathology 172:325-335 (1994)]. However, several of these studies address hematological disorders where genetic changes

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

are assessed in freshly fixed smears from bone marrow aspirates or peripheral blood specimens. United States Patent No. 6,573,043 describes combining morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample.

Thus, the instant application discloses the first author, journal, volume, year, and page numbers for the Anastasi publications (6 pages each) and the van Lom (5 pages), Wolman (8 pages), and Zitzelberger publications (11 pages). It is respectfully asserted that one of skill in the art would know where to find these publications, and would be able to read the very small number of pages contained therein. Rather than “omnibus” language, the instant application uses specific citations that are accessible to skilled persons in the art.

Third, Applicants point to the level of particularity that is required by the courts. In *National Latex Products*, the Sixth Circuit held that a brief statement was sufficient for incorporation by reference: “A suitable apparatus for continuous internal casting is shown in the application of Henry Martin and Paul Rekettye, Serial No. 179,726 filed August 16, 1950...” *National Latex Products*, 274 F.2d at 230; U.S. Pat. No. 2,629,134, col. 4. In *In re Fried*, The Court of Customs and Patent Appeals held that a short statement was sufficient for incorporation by reference: “The...steroid reactants can be prepared as disclosed in the applications of Josef Fried, Serial Nos. 489,769 and 515,917, filed February 21, 1955, and June 24, 1955, respectively.” *In re Fried*, 329 F.2d 323, 325 (C.C.P.A. 1964). Compared to these statements of incorporation, Applicants have certainly provided sufficient particularity.

For all of these reasons, Applicants respectfully assert that the specification includes proper incorporations by reference. Withdrawal of this objection is respectfully requested.

§ 112 First Paragraph - written description

Claims 1-13 and 33 have been rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement (Office Action, page 5). The Examiner states that the claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one of skill in the art that the Inventors

had possession of the claimed invention and raised a number of issues to support the rejection.
Id. Each one of these issues is addressed below.

First, the Examiner states that the claimed method encompasses the preparation of fixed material from cells or tissue derived from any plant, as well as from any tissue found in any mammal, and therefore lacks sufficient written description (Office Action, page 8). For this rejection, the Examiner relies on the court's decision in *University of California v. Eli Lilly and Co.* 43 USPQ2d 1405 (Fed. Cir. 1997) (See, Office Action, sentence spanning pages 7 and 8). Applicants respectfully traverse as follows.

University of California is clearly distinguished from the instant case. In *University of California*, the claims at issue were directed to recombinant plasmid with an insert that encodes insulin. *University of California*, 43 U.S.P.Q.2d at 1401. The Court held that the claims required human insulin-encoding cDNA and such cDNA was not disclosed in the specification. *University of California*, 43 U.S.P.Q.2d at 1404-05. Because of this, the Court affirmed a lower court decision that the claims are invalid. *Id.* at 1405.

In contrast to the University of California case, Applicants' claimed invention is directed to methods of preparing tissues for *in situ* hybridization after the tissues samples have been prepared (See, e.g., claim 2 of the instant Application). In some instances, the prepared tissue is already fix treated (See, e.g., claim 1 of the instant Application). Therefore, the focus on the written description for such methods is misplaced. Applicants traverse this rejection because the claims are not directed to methods of preparing tissue samples or fixing tissue. See, e.g., independent claims 1, 10 and 32. Methods of preparing tissues from various cell types, including methods for preparing fix treated tissue, are not claimed by the pending claims. Since preparation of tissues and fixed treated tissue is not claimed, it is immaterial whether the instant specification provide adequate description of how to prepare tissues from various cell types.

Furthermore, the preparation of fixed treated tissue is well known at the time the instant application was filed (i.e., November 20, 2002). For example, methods for fixing various tissues are listed in *Manual of Histological Staining Method of the Armed Forces Institute of Pathology*

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

(3rd edition (1960) Lee G. Luna, HT (ASCP) Editor, The Blakston Division McGraw-Hill Book Company, New York (Exhibit 1)) and in the *Armed Forces Institute of Pathology Advanced Laboratory Methods in Histology and Pathology* (1994) Ulreka V. Mikel, Editor; Armed Forces Institute of Pathology, American Registry of Pathology, Washington, D.C. (Exhibit 2)).

In fact, methods of preparing fixed tissue was sufficiently advanced by the time the instant Application was filed that automated tissue fixing machines were commonly patented. Automated tissue fixing technology are claimed in numerous issued US patents including, at least, US 6,058,788 (automated machine for fixing tissues (Exhibit 3)), US 4,834,943 (tissue processor for fixing and embedding resin impregnated specimens (Exhibit 4)), US 4,688,517 (automated tissue fixation and embedding (Exhibit 5)), US 3,889,014 (machine for automatic fixation, dehydration, and clearing of tissue specimens (Exhibit 6)). Other examples of automated tissue processing and fixing machines are reported in 3,526,203 (Exhibit 7); 3,771,490 (Exhibit 8); 3,227,130 (Exhibit 9); 2,959,151 (Exhibit 10); 2,386,079 (Exhibit 11); 2,341,198 (Exhibit 12); 2,157,875 (Exhibit 13); 3,400,726 (Exhibit 14); 2,681,298 (Exhibit 15); and 2,684,925 (Exhibit 16). In summary, methods for preparing fixed treated samples from multiple tissues were well known at the priority date of the instant patent Application and automated machines and methods for fixing tissues have been the subject of numerous patents.

Second, the Examiner asserts that the disclosure provides one working example and fails to disclose any other conditions for performing the claimed method. (Office Action, page 7, first paragraph). Applicants traverse and note that Examples are not required in a Specification. See, MPEP §2164, “[c]ompliance with the enablement requirement of 35 U.S.C. [§] 112, first paragraph does not turn on whether an example is disclosed.” The instant specification have provided a working Example and sufficient description throughout the text to practice the claimed invention. Specific teachings that may be found in the Specification is detailed below. For example the process of preparing a sample of fixed treated tissue is described in the Specification on page 16 line 7 to page 17 line 17 and on page 23 line 22 to page 25 line 11. The process of preparing cell lines and tissue for FISH is described in the Specification on page 17, line 19 to page 18 line 22. The process of fluorescence in situ hybridization (FISH) is described

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

in the Specification on page 18 line 24 to page 21 line 14. In addition, the Example section provides description for at least one method for performing the claimed invention. For these reasons, Applicants assert that the instant specification has provided a working Example and sufficient description throughout the text so that one of skill in the art would know how to practice the claimed invention without undue experimentation.

Third, the Examiner assert that the specification does not disclose the composition of the a solution for deparaffinization and antigen retrieval. (Office Action, page 7). Applicants traverse this basis for rejection because solutions for performing deparaffinization and antigen retrieval was well known and commercially available at the time the instant application was filed (i.e., July 21, 2003). For example, it was known at the time the instant application was filed that “Declere™” solution from Cell Marque or “Reveal™” solution from BioCare Medical can both perform deparaffinization and antigen retrieval steps using just one solution. As support, Applicant submit a material data sheet from Sigma-Aldrich which shows that the Declere™ solution was available since at least August 2001 (See, Exhibit 17, date stamp of August 2001 on the bottom right hand corner). Applicants asserts that it is not necessary for the instant Specification to list the formulation of solutions that are well known and commercially available to those of skill in the art.

Fourth, the Examiner asserted that the specification does not provide “an adequate description of any probe, labeled or otherwise” (Office Action, page 7, first paragraph) as a basis for rejection. It is Applicants’ position that the description of probes and labels is immaterial to instant pending claims. The claimed methods and compositions, as embodied in pending claims 1-13 and 33 do not encompass probes or labels and do not contain language directed to probes or labels. It is immaterial whether probes and labels are described in the specification because only the claimed invention is required to be supported by the specification. Since the claimed do not recite probes or labels, the basis of rejection is moot.

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

For the reasons stated above, it is therefore asserted that the instant application has met the requirements for written description for the claimed invention under 35 U.S.C. 112. Withdrawal of this ground of rejection is respectfully requested.

§ 112 First Paragraph - enablement

Claims 1-13 and 33 stand rejected under 35 U.S.C. § 112 first paragraph as allegedly nonenabling. Applicants traverse.

The Examiner listed two basis for rejecting the claims. Each of the Examiner's basis of rejection is discussed below.

First, the Examiner contends that the claims are not enabled because the claims encompasses using virtually any temperature, pressure and duration and that the disclosure fails to provide conditions under which the claimed method can be practiced for the full genus of cells and tissues. As discussed above, the claimed invention is directed to a method of prepared cell lines and tissues and such methods are well known. Furthermore, methods for pressure cooking a sample are well known. For Example, "pressuring cooking" is described in the review article by Shi et al. (Antigen Retrieval Immunohistochemistry: Past, Present, and Future, J. Histochemistry and Cytochemistry 45:327-43 (1997) (Exhibit 18)) and also by Miller et al. (Heat-induced epitope retrieval with a pressure cooker - suggestions for optimal use. Appl. Immunohistochem. 3:190-93 (1995) (Exhibit 19)) and Norton et al. (Brief, High-Temperature Heat Denaturation (Pressure Cooking): A Simple And Effective Method Of Antigen Retrieval For Routinely Processed Tissues., J. Pathol. 173:371-79 (1994) (Exhibit 20)). In addition, solely in an effort to expedite prosecution, Applicants have amended the independent claims to recite the pressure cooking is performed at a temperature of 125°C and a pressure of between 20 to 24 PSI. For these reasons, Applicants assert that a person of skill in the art would know the proper temperature, pressure and other conditions to practice the invention without undue experimentation.

Second, the Examiner alleged that the specification is not enabled because "it fails to set forth a reproducible procedure whereby the resultant product is used to overcome art-recognized

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

issues of enablement - namely, a problem set forth in Muhlhahn et al. (US 2004/0038270) associated with cells or tissue detaching from a slide while FISH is conducted" (Office Action, page 9, lines 19-24).

Applicants note that Fluorescence In Situ Hybridization (FISH) is an established technique widely accepted in the art as a valid and verifiable approach for clinical diagnosis and research. Numerous researchers and other persons of skill in the art have successfully used FISH in spite of the alleged problems cited by the Examiner. For Example, numerous patents have been issued for methods involving FISH. See, e.g., US 6,548,259 entitled multiparametric fluorescence *in situ* hybridization (Exhibit 21); US 6,506,563 entitled multiparametric fluorescence *in situ* hybridization (Exhibit 22); US 6,221,607 entitled automated fluorescence in situ hybridization detection of genetic abnormalities (Exhibit 23); US 6,136,540 entitled automated fluorescence in situ hybridization detection of genetic abnormalities (Exhibit 24); US 6,043,037 entitled rapid method for measuring clastogenic fingerprints using fluorescence *in situ* hybridization (Exhibit 25); US 6,007,994 entitled multiparametric fluorescence *in situ* hybridization (Exhibit 26); 5,792,610 entitled method for conducting multiparametric fluorescence *in situ* hybridization (Exhibit 27); and US 5,759,781 entitled multiparametric fluorescence *in situ* hybridization (Exhibit 28). Furthermore, fluorescence *in situ* hybridization (FISH) has been used in a variety of areas of research and clinical diagnostics for over 10 years (See, e.g., Gray, J. W. et al., Curr Opin Biotech 3:623-631 (1992) (Exhibit 29); Xing, Y. et al., In: The Causes and Consequences of Chromosomal Aberrations. I. R. Kirsch Ed. CRC Press, Boca Raton, pages 3-28 (1993) (Exhibit 30)).

Based on the numerous reports of successful applications of FISH, Applicants respectfully asserts that ordinary artisan can practice FISH without undue experimentation in spite of the alleged problems "with cells or tissue detaching from a slide while FISH is conducted" (Office Action, page 9, lines 19-24). In view of the detailed description, working example, and well-known techniques and factors disclosed in the instant application, it is respectfully asserted that the application provides sufficient guidance for the claimed methods

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

and composition. Withdrawal of the rejection of pending claims 1-13 and 33 is respectfully requested.

§ 103

Claims 1-13 and 33 stand rejected under 35 U.S.C. § 103 as allegedly obvious over Engle and Baschong. Applicants traverse.

There is no motivation to combine Baschong with Engel because the two references are directed to incompatible methods.

Engel is directed to inspection of immunostained tissue section by light microscopy at low magnification of 10x or 40x. See, Engel, page 38, col. 1, first paragraph. Because Engel's method uses light microscopy, it does not use an excitation frequency to stimulate fluorescence and it cannot detect autofluorescence (or any fluorescence). For this reason, autofluorescence cannot be a problem in Engel's method. In contrast to Engel, Baschong is directed to controlling autofluorescence in confocal laser scanned tissue. See, Baschong, title. A person of skill in the art would find no reason to combine the autofluorescence technique of Baschong with Engel because autofluorescence is not a problem and is, in fact, undetectable in Engel's low magnification (10x to 40x) light microscopy method.

There Is No Expectation of Success Even If Engel and Baschong Were Combined

There is no expectation of success even if Baschong is combined with Engle. Baschong have conflicting results and states “the result of the present study highlight the fact that there is no general recipe available for the control of autofluorescence. Success was found in a tactical approach that can be summarized as choice of the appropriate reagent(s) by trial and error . . .” Baschong, page 1571, first column. Since Baschong have made no suggestions as to a method for reducing autofluorescence, a combination of Baschong and Engle, is merely an experiment which, in Baschong's characterization, involves choosing the appropriate reagents by trial and

error. Further, as discussed in the next section, a combination of Baschong and Engel in any event would not lead to Applicants' claimed invention.

Even If Baschong And Engle Were Combined, It Would Not Lead To Applicants' Claimed Methods And Compositions

The claimed invention, is directed to a method used for preparing cell-line and/or tissue samples. In the method, cells are pressured cooked and treated with ammonia-ethanol and sodium borohydride (See, e.g., claims 1 and 33). Other claims are directed to compositions comprising a fixed-treated tissue, ammonia-ethanol and sodium borohydride.

Baschong teaches that a combination of ammonia-ethanol treatment and sodium borohydride treatment is undesirable by stating:

“[t]o our surprise, treatment with borohydride induced bright autofluorescence in erythrocytes that had otherwise remained inconspicuous (Figure 1F). **This undesirable effect** was slightly diminished by adding ammonia-ethanol (Figure 1G) or sudan [black B] (Figure 1H) and even better if both reagents were combined (Figure 1I). Nevertheless, borohydride treatment once applied, autofluorescence in erythrocytes could not be completely abolished (Figure 1I).” Baschong at page 1567 (emphasis added).

As discussed above, Engel refers to wet heat treatment for paraffin wax embedded tissues and is silent on the suppression of autofluorescence. One of skill in the art, in reading Baschong and Engle, would be discouraged from using a combination of borohydride and ammonia ethanol because Baschong states that the undesirable autofluorescent effect of borohydride treatment “could not be completely abolished.”

In fact, the cited references teaches away from the claimed invention. In contrast to the undesirable effects of borohydride and ammonia ethanol, Baschong states “A near to total absence of autofluorescence was attained by treatment with ammonia-ethanol and Sudan [black B].” Baschong at page 1567. Thus, there is no motivation to combine Baschong with Engel to

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

come up with Applicant's claimed invention. At best, a combination of Baschong and Engel would lead to the use of ammonia-ethanol and Sudan black B which does not contain all the recitations of Applicants' claims.

For the reasons stated above, Applicants believe that the rejection of claims 1-13 and 33 under 35 U.S.C. § 103 was improper and should be withdrawn in view of Applicants arguments.

Applicant: Paola CAPODIECI, et al.
Application No. 10/624,233
Response/Amendment Dated March 30, 2005
Reply to Office Action of September 30, 2004

CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and remark, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

While Applicants believe that no additional fees are due, the Director is authorized to charge all fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 24817-503, Customer No. 35437.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Eric Sinn, Reg. No. 40,177
MINTZ LEVIN, *et al.*
666 Third Avenue, 24th Floor
New York, NY 10017
Telephone: (212) 935-3000
Telefax: (212) 983-3115

Date: March 30, 2005

Armed Forces Institute of Pathology

**Advanced
Laboratory
Methods in
Histology and
Pathology**

Ulrika V. Mikel, Editor

**Armed Forces Institute of Pathology
American Registry of Pathology
Washington, DC**

Armed Forces Institute of Pathology

Advanced Laboratory Methods in Histology and Pathology

Ulrika V. Mikel, Editor



**Armed Forces Institute of Pathology
American Registry of Pathology
Washington, DC
1994**

Available from
American Registry of Pathology
Armed Forces Institute of Pathology
Washington, DC 20306-6000

ISBN: 1-881041-13-1
1994

The use of general descriptive names, registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The views of the authors and editor do not purport to reflect the positions of the Department of the Army or the Department of Defense.

Authors

Virginia A. Achstetter, AA, HT (ASCP), Department of Genitourinary Pathology, AFIP

Lila R. Adams, MLT, HT (ASCP), Division of Immunopathology, Department of Cellular Pathology, AFIP

Frank A. Avallone, BS, Supervisor, Department of Genitourinary Pathology, AFIP

Gary L. Bratthauer, BA, MT (ASCP), Division of Molecular Pathology, Department of Cellular Pathology, AFIP

Leigh Buckner III, BS, CT (ASCP), Supervisor, Cytology Laboratory, Walter Reed Army Medical Center

Robert E. Cunningham, MS, Division of Biophysics, Department of Cellular Pathology, AFIP

Annette Geissel, HT (ASCP), Division of Quantitative Pathology, Department of Cellular Pathology, AFIP

Carole E. Gregory, BS, Division of Neuromuscular Pathology, Department of Neuropathology, AFIP

Joe L. Griffin, PhD, Division of Quantitative Pathology, Department of Cellular Pathology, AFIP

Ulrika V. Mikel, BS, MGA, Supervisor, Division of Quantitative Pathology, Department of Cellular Pathology, AFIP

Tracy L. Raber, BS, CT (ASCP), Cytology Laboratory, Walter Reed Army Medical Center

Ann H. Reid, MA, Division of Molecular Pathology, Department of Cellular Pathology, AFIP

Isabell A. Sesterhenn, MD, Staff Pathologist, Department of Genitourinary Pathology, AFIP

Denise Y. Young, BS, Department of Genitourinary Pathology, AFIP

Contents

■ Chapter 1

Immunohistochemistry: Antigen Detection in Tissue 1

Gary L. Bratthauer and Lila R. Adams

Avidin-Biotin Complex Method for Antigen Detection	3
Materials and Solutions	6
Procedure	8
Peroxidase-Antiperoxidase Method for Antigen Detection	12
Procedure	12
Alternatives	13
AEC Chromagen Alternative	13
Additional Alternatives	14
Interpretation of Results	17
Problem Solving	20
Laboratory Organization	23
Antibody Selection	23
Case Management and Tracking Systems	24
Quality Control	25
Appendix 1: Antigen Detection in Tissue by ABC Immunohistochemistry	27
Appendix 2: List of Reagent Antibodies	30

■ Chapter 2

In Situ Hybridization 41

In Situ Hybridization of Viral Inclusions 41

Robert E. Cunningham

Materials and Solutions	44
Procedure	49
How to Avoid Problems and Aids for Troubleshooting	52

Interphase Cytogenetics in Paraffin Sections by In Situ Hybridization 58

*Frank A. Avallone, Virginia A. Achstetter, Denise Y. Young,
and Isabell A. Sesterhenn*

Materials and Solutions	59
Hybridization Procedure	64
ISH Dry Method	65
ISH Wet Method	66
Troubleshooting	67

■ *Chapter 3*

Polymerase Chain Reaction 77

Ann H. Reid

Quality Assurance	80
Extraction of DNA from Formalin Fixed Paraffin-Embedded Tissue	81
Materials and Solutions	81
Procedure	82
Optimizing PCR for a Specific Application	84
Primer Design	84
Controls	84
Optimization	85
Programming the Thermal Cycler	87
The Polymerase Chain Reaction	88
Materials and Solutions	88
Procedure	89
Agarose Gel Electrophoresis	92
Materials and Solutions	92
Procedure	93
Interpreting Ethidium Bromide-Stained Gels	94
Southern Blotting, Hybridization, and Autoradiography	96
Materials and Solutions	96
Procedure	97
Blotting	97
Hybridization	98
Washing	98
Interpreting Autoradiograms	99
End-labeling of Oligonucleotide Probes	101
Materials and Solutions	101
Procedure	102
End-Labeling DNA Size Markers	103
Materials and Solutions	103
Procedure	105

■ *Chapter 4*

Preparation of Nuclei for Flow Cytometry 111

Annette Geissel and Joe L. Griffin

Isolation and Staining of Nuclei from Paraffin-Embedded Tissues	114
Materials and Solutions	114
Procedure	118
Procedure at a Glance	121
How to Avoid Problems and Aids for Troubleshooting	123
Isolation and Staining of Nuclei from Fresh Tissues for Flow Cytometry	125
Isolation and Staining of Mononuclear Cells from Whole Blood for Flow Cytometry	126
Quality Control	127

■ *Chapter 5*

**Quantitative Staining Techniques
for Image Cytometry 131**

Ulrika V. Mikel

Absorbance Cytometry	131
Fluorescence Cytometry	133
Instrumentation	133
Data Collection	134
Staining Methods for Absorption Cytometry	136
The Classical Feulgen Stain	136
Azure A Feulgen Stain	139
Thionin Feulgen Stain	141
Acriflavine Feulgen Stain	143
Gallocyanine-Chrome Alum.....	145
Rapid Gallocyanine-Chrome Alum Stain	147
Staining Methods for Fluorescence Cytometry	149
Acriflavine Feulgen Stain	150
Acridine Orange Stain	152
Propidium Iodide Stain	154

■ *Chapter 6*

Enzyme Histochemistry of Skeletal Muscle 161

Carole E. Gregory and Joe L. Griffin

Flash Freezing of Muscle Biopsy Tissue	163
Materials and Supplies	163

Procedure	164
Sectioning	166
Staining Methods for Muscle Biopsies	168
NADH (NADH diaphorase) Stain	168
ATPase (adenosine triphosphatase) Stain	170
RATPase (reversal of adenosine triphosphatase) Stain	173
Nonspecific Esterase Stain	176
Alkaline Phosphatase Stain	178
Myoadenylate Deaminase Stain	180
Modified Gomori's Trichrome Stain.....	182
Hematoxylin and Eosin Stain.....	184
Succinic Dehydrogenase (SDH) Stain	186
Phosphorylase and Branching Enzyme Stain	188
Phosphofructokinase (PFK) Stain.....	191
Periodic Acid-Schiff Reaction (PAS) Stain	193
Osmium Tetroxide-p-Phenylenediamine Lipid Stain	196
Oil Red O Stain in Propylene Glycol	198
How to Avoid Problems and Aids for Troubleshooting	200

■ *Chapter 7*

Cytopathology Techniques207

Tracy L. Raber and Leigh Buckner, III

Fixation of Smears	209
Slide Preparations of Cytology Samples	210
Membrane Filters	211
Toluidine Blue Test.....	213
Direct Smears	214
Saccomanno Method for Preparation of Sputa	215
Cell Block Preparation	217
Cytospin Preparation	219
Staining Procedures	221
Papanicolaou Stain	221
Papinicolaou Stain for Filters	224
Quality Control of the Papanicolaou Staining Technique	226
Destaining of Slides	227
Diff-Quick Stain	228
Giemsa Stain.....	230

Index239

Immunohistochemistry:

Antigen Detection in Tissue

Gary L. Brathauer and Lila R. Adams

INTRODUCTION

Immunohistochemistry involves the detection of specific chemical substances within tissue by the use of derived antibodies to the substances. Antibodies are applied to tissue sections and allowed to bind to their corresponding antigen. A detection system is then employed to identify the location of these antibodies using marker molecules that can be visually recorded.

Antibodies are produced from the introduction of a specific chemical substance to the immune system of an unrelated species. The immune system has the innate ability to recognize, via specific receptor molecules, virtually any combination of amino acids, carbohydrates, or lipids and respond. This recognition is dependent on many factors, one of which is size. A molecule of several hundred daltons is required to initiate receptor recognition and immune response. This molecule is called the antigen. Many proteins are large enough to elicit an immune response and therefore are antigenic. Many other molecules, or small proteins, are not and must first be attached to a larger molecule. These small molecules can then be recognized by the immune system and are called haptens. When a foreign molecule is introduced to the body, it is recognized as such in conjunction with the particular human leukocyte antigen (HLA) receptors on macrophages. The macrophage digests the molecule and presents certain combinations of external groups of atoms called epitopes on the surface of the cell. The epitope is then brought into contact with helper T-cell lymphocytes, which help present the epitope to B-cell lymphocytes. The B cells synthesize immunoglobulin protein

2

In Situ Hybridization

This chapter covers the *in situ* hybridization technique on paraffin-embedded material. The procedure can be varied in many different ways. We have chosen to present two versions, each discussed by a different department at the AFIP.

In Situ Hybridization of Viral Inclusions

Robert E. Cunningham

INTRODUCTION

The advances in immunology and molecular biology have revolutionized diagnostic medicine and have greatly contributed to biomedical research as a whole. One of the techniques that utilizes both immunology and molecular biology is *in situ* hybridization (ISH). *In situ* is Latin for "in its original place" and hybridization means "to cause the production of a hybrid, a cross"; in this case, a hybrid of single-stranded genomic DNA and single-stranded probe DNA. It accomplishes this by enjoining powerful methodologies from the two systems. The diversity of the immunologic detection capability and the exquisite sensitivity of specific DNA base recognition together provide a new powerful tool for diagnosis and research. Appropriate immunological stains enable recognition of phenotypic changes that may reflect genotypic alterations. ISH can reveal those genotypic changes as well as oncogene expression, chromosomal mapping, infectious disease detection,

—3—

Polymerase Chain Reaction

Ann H. Reid

The polymerase chain reaction (PCR) is used to make large numbers of copies of a specific DNA sequence. Normal human genes are present at the level of two copies per cell, and viral or bacterial pathogens may be present at even lower concentrations. Standard laboratory techniques are unable to detect specific DNA sequences at such low levels. PCR allows the DNA to be copied over and over again (a process called amplification) until it is present in sufficient quantity to be easily detected. PCR can be used to demonstrate the presence or absence of a gene; to detect mutation, amplification, or rearrangement of a gene; and to detect viral or bacterial DNA.

The DNA double helix is made up of two strands, each of which consists of a chain of deoxyribonucleotides. The backbone of the helix is formed by a series of phosphodiester bonds in which the 5' carbon of one sugar is bound to the 3' carbon of the next sugar by a phosphate. Thus, a DNA strand is said to have directionality. In a double helix, one strand runs in the 5' to 3' direction, while its complement runs in the 3' to 5' direction. The nitrogenous bases stack one on top of the other within the helix. There are four nucleotides that make up DNA: two purines, adenine and guanine, and two pyrimidines, cytosine and thymine. Each of these is bound by a hydrogen bond across the double helix with only one partner; thus, adenine is always found paired to thymine, and guanine is always found paired to cytosine. The exclusivity of this binding means that the sequence of one strand of DNA can always be deduced from the sequence of the other. (For more information on DNA structure, see reference 3.) The polymerase chain

Preparation of Nuclei for Flow Cytometry

Annette Geissel and Joe L. Griffin

INTRODUCTION

Flow-cytometric analysis, in contrast to slower static methods of DNA quantitation, lets us quickly determine the nuclear DNA content of large numbers of cells. DNA flow studies began in 1969 by Van Dilla et al. Initially these studies were limited to the use of hematopoietic tissues, such as peripheral blood, bone marrow cells, and lymphoid tissues. In the 1970's, methods for extraction of whole nuclei from fresh-frozen and/or fixed solid tissues were developed by various laboratories, which in turn lead to experimentation on fixed, paraffin-embedded tissues. Studies on archival material make use of methods developed in the early 1980's for isolating and staining nuclei from paraffin-embedded tissues (Hedley et al. 1983, Hedley 1989, McLemore et al. 1990, Heiden et al. 1991). Recovery of cells from thick paraffin sections allows retrospective studies on collections of tumors and correlation of flow data with clinical history.

The methods described here reflect our experience and include modifications to previously published methods.

DNA measurements by flow cytometry are based on the ability of certain fluorescent dyes to bind specifically and in direct proportion to DNA under certain staining conditions. The principal dye for staining DNA is propidium iodide, which binds by intercalation (insertion) between the double strands of the DNA molecule. Nuclear fluorescence produced by laser excitation is measured and recorded as nuclei flow rapidly in single file through the laser beam. A computer records individual

Quantitative Staining Techniques for Image Cytometry

Ulrika V. Mikel

INTRODUCTION

Over the last few decades image cytometry has become a tool increasingly applied to research in pathology. One of its main objectives is to determine the amount of deoxyribonucleic acid (DNA) in tumor cells in order to detect if the cells are aneuploid (have too much or too little DNA) and to determine how rapidly they are dividing or proliferating. The DNA content is determined by the amount of nuclear stain uptake in cell populations. This is done by measuring the optical density of cells stained with absorbance stains, which bind to nuclear chromatin in proportion to the amount of DNA, or the fluorescence intensity of cells stained with fluorochromes, which also bind stoichiometrically, i.e., in a proportional way. As pathologists have become more familiar with the technique, some of them are known to have used image cytometry as an aid in the diagnosis and prognosis of tumors. It is quite possible that the importance of this technique will grow and, in the future, routinely be applied and used in most histology laboratories.

Absorbance cytometry

The most commonly used stain for quantitative evaluation of nuclear DNA is the Feulgen reaction. This reaction is based upon cleavage of the purine-deoxyribose

— 6 —

Enzyme Histochemistry of Skeletal Muscle

Carole E. Gregory and Joe L. Griffin

INTRODUCTION

This chapter briefly describes methods for staining frozen unfixed sections of muscle biopsies, as applied in the Muscle Laboratory, Department of Neuropathology, AFIP. Enzyme histochemical stains are usually the most useful diagnostic tools for the pathologist interpreting muscle biopsies. Those stains, with a few nonenzymatic stains used for general morphology and localization, are described in this chapter. While our standard biopsy also includes clamped muscle tissue for electron microscopy and for embedding in paraffin after formalin fixation, those topics are not considered here.

Figures 6-1 to 6-12 illustrate artifacts and stains. At the end of the chapter are references to publications that include many photomicrographs of normal and diseased muscle stained by histoenzymatic and related methods.

Some stains answer a yes-no question about a single enzyme to reveal rare deficiency states. Other stains reveal patterns useful for pathologic interpretation, such as NADH and ATPase to show fiber types (type grouping, type predominance, type-specific atrophy, etc.), esterase for denervation (angular atrophic esterase-positive fibers), ATPase for reinnervation (intermediate-density fibers), and alkaline phosphatase for inflammation.

The differences between type 1 and type 2 fibers are summarized in this memory sentence: "One mighty slow, fat, red ox." Type 1 fibers contain more mitochondria, are slow twitch, contain more fat, predominate in what used to be called red

Cytopathology Techniques

Tracy L. Raber and Leigh Buckner, III

INTRODUCTION

Over the last several decades, cytology has become a widely accepted and integral component of pathology. It is routinely practiced, even in small laboratories where the cytotechnologist and/or cytopathologist may have to rely on help from the histology laboratory. This chapter is intended as a guide of preparatory techniques in cytopathology for histotechnologists, and other technical personnel, who find themselves helping out in a cytology laboratory. Thus, this is an abbreviated version of methods in cytology and not intended for cytotechnologists.

Cytology deals with the structure, function, multiplication, life history, and pathology of cells. Cytopathology implies changes to cells in disease, and cytology samples are examined for their nuclear and cytoplasmic details. Changes in cell patterns help to separate normal and abnormal cells from each other. Cytology preparations can therefore be diagnostic, or helpful in the diagnosis, of disease.

Cell samples can be collected in several ways. The person who handles cytology specimens must be aware that the preparation of cytology samples varies depending upon the type of specimen and the collection method. Gynecologic material (Pap smears) and fine-needle aspirations are smeared and fixed prior to arrival in the cytology laboratory. They are fixed with alcohol-based spray fixative or 95% ethyl alcohol. Watery specimens, or sparsely cellular specimens, such as urines, cerebrospinal fluids (CSFs), and body cavity fluids must be placed on filters or concentrated for optimal cell recovery. Centrifugation concentrates cells into a pellet from which smears, or a cell block, can be made. Cytocentrifugation

— INDEX —

A

- ABC See: avidin-biotin complex method
Absorbance cytometry 131
Absorption 21
Absorption filter 144
Acetate buffer, skeletal muscle stain reagent 173, 189
Acetic acid, 0.2%, skeletal muscle stain reagent 182
Acid hydrolysis, Feulgen reaction 132, 136
Acridine orange stain 133, 152, 153
Acriflavine 132, 150
Acriflavine Feulgen stain 143, 150
Adenosine 5'-triphosphate (ATP), skeletal muscle stain reagent 170, 171, 174
Adenosine triphosphatase (ATPase), skeletal muscle stain 170
Adenosine monophosphate deaminase (AMP-DA), skeletal muscle stain 180
Adenosine-5-monophosphate (AMP), skeletal muscle stain 188
AEC, amino ethyl carbazole 13, 42, 43 See also: Chromogens
Affinity columns 22
Agarose 92
Agarose gel 78, 96
electrophoresis 78, 92
interpretation 94
Alkaline phosphatase 14, 178
Alpha-naphthyl acetate in acetone, skeletal muscle stain reagent 176
Amino ethyl carbazole (AEC) 13, 42, 43 See also: Chromogens
Ammonia water, hematoxylin stain reagent 8
Ammonium hydroxide (blueing bath), Papanicolaou stain reagent 222
Ammonium sulfide, skeletal muscle stain reagent 171, 173
Analyte 8
Aneuploid, aneuploidy 113, 131
histogram 112, 135
Annealing 42
Anode lead 93
Antibody 1, 2, 20, 24
antibody selection 23
Antigen 1, 20
antigen-retrieval method. 15
Antigen detection in tissue by ABC immunohistochemistry 27
Antisense strand 78
Antisera 20
Archival tissue 123

Artifacts 17, 19, 225
ATP (adenosine 5'-triphosphate), skeletal muscle stain reagent 170, 171
ATPase (adenosine triphosphatase) 170
Autoclave seals 11
Autoclave tape 11
Automated PCR 78
Autoradiogram, PCR 96,
interpretation 100
Avidin 3, 4
Avidin-biotin complex (ABC) 3, 7, 27, 59, 66
Avidity, immunohistochemical reactivity 21
Azure A Feulgen stain 139

B

B-cell lymphocyte 1
Background reactivity
immunohistochemistry 18
in situ hybridization 53
Bacterial pathogen, detection of, PCR 77
Bands, PCR 95
Basic fuchsin (pararosaniline) 132
Basic incubation solution, skeletal muscle stain reagent 191
Beads, microsphere 127
Biohazard bags 11
Biotin 3, 4
biotin-labeled DNA probes 43, 59
biotinylated enzyme 43
biotinylated secondary antibody 27
Blocking solution
immunohistochemistry 9
in situ hybridization 60, 64
Blot, Southern 96
Blueing bath, ammonium hydroxide, Papanicolaou stain reagent 222
Borax-boric acid buffer, skeletal muscle stain reagent 178
Bouin's fixative 138
Branching enzyme (1,4-amyo:1,6-transglucosidase), skeletal muscle 188
Branching enzyme and phosphorylase solution, skeletal muscle stain reagent 189
Buffers
CIP 104
citrate 152
kinase 102, 104
lower buffer 90
PBA 116
PBS 6, 21, 45, 61, 66, 116
PBSE 45
PCR 89

L

phosphate 6, 145, 147, 168, 186, 230
sodium barbital 173
Tris 46, 60, 81, 88, 102, 103, 115
upper buffer 91

C

Calcium chloride, skeletal muscle stain reagent 170, 173
Calf intestinal phosphatase (CIP), PCR reagent 103
 CIP buffer 104
Carbowax, cytopathology techniques 209, 215
Carnoy's fixative 132
Carrier DNA, *in situ* hybridization 46, 59
Case Management and Tracking Systems, immunohistochemical laboratory 24
Cell block preparation 217
Cell count, flow cytometry 119, 121
Cell cycle 134
Cell suspensions, flow cytometry 113
Central cores, skeletal muscle stain result 169
Channel, flow cytometry 113
Charged sites, immunohistochemistry 18
Chatter, muscle biopsy problem 201
Chick erythrocytes, flow cytometry controls 123, 127
Chromogens
 AEC 48, 13
 DAB (diaminobenzidine) 9, 48, 63
Citrate buffer 152
Cobalt chloride
 immunohistochemistry 14
 muscle stain, ATPase reaction 171
 muscle stain, reverse ATPase reaction 173
Control, PCR
 negative, paraffin 85
 positive 85
 positive, PCR 85
 control gene 85
 control primers 85
Copper sulfate, enhancer for DAB stain 60, 63
Cornflaking, cytopathology preparation problem 225
Count of nuclei 119
Counterstains
 immunohistochemistry 8
 in situ hybridization 44
Cross-contamination, cytopathology preparation problem 225
Cross-reactivity, immunohistochemistry techniques 19
Cryostat 166
Crystal/Mount, slide mounting medium 13, 14, 44, 150, 152, 155

Cytology slide preparation
cell block preparation 217
cytospin preparation 219
direct smears 214
membrane filters 211
Saccomanno method for preparation of sputa 215

Cytology staining preparations
destaining of slides 227
Diff-Quik stain 228
Giemsa stain 230
PAP stain 221
procedure for filters 224
toluidine blue test 213

CYTOPATHOLOGY TECHNIQUES 207

Cytosine 77
Cytospin 219
Cytospin preparation 219

D

DAB (3,3'-diaminobenzidine) 3, 4, 10, 27, 42, 43, 60 See also: Chromogens
DAPI, flow cytometry stain 115, 120
Data collection, image cytometry 134
Decalcify 16
Denaturation
 in situ hybridization 42
 PCR 87
Denaturation solution 62
Denatured DNA 86
Deoxynucleoside triphosphates (dNTPs), PCR 89
Detection complex, in situ hybridization 48
Detection, immunohistochemistry
 process 4
 system 1, 2, 21
Determinants, immunohistochemistry 2
Dextran sulfate solution, in situ hybridization reagent 46
Diaminobenzidine (DAB) 7 See also: Chromogens
Diastase solution, periodic acid-Schiff reaction (PAS) reagent 193
Diff-Quik stain, cytopathology stain 208, 214, 228
Digestion solution
 immunohistochemistry 8
 in situ hybridization 43, 46, 65
 PCR 83
 flow cytometry 115, 119
Diluted serially, immunohistochemistry 23
Diploid 134
 cell population and histogram 112, 113, 135

L

diploid plus aneuploid populations 112, 135
Direct smears, cytopathology techniques 214
Disodium salt, ATPase stain reagent 170
Dithiothreitol solution
 PCR 102, 104
 myoadenylate deaminase stain 180
DNA 42, 58, 77, 131
 bacterial, detection of 77
 carrier 62
 denatured 86
 double helix 77
 double-stranded 42, 77
 histograms 112, 135
 hybridization 43, 78
 markers 103
 radioactively labelled probe 78
 sequence 42
 single-stranded DNA (ssDNA) 42, 78
 single-stranded genomic DNA 41
 single-stranded DNA probe 41
 size markers 92
 target 86
 template 78
 viral, detection of 77
DNA probe, *in situ* hybridization 42, 43
 (negative control) 47
 (positive control) 47
dNTPs, PCR reagent 89
Documentation, immunohistochemistry laboratory 25
Double helix 42, 77

E

Edge artifact, immunohistochemistry 18
EDTA, 200mM, *in situ* hybridization reagent 44
Electrophoresis, PCR 78
Elmer's glue 8
Emission spectrum 133
End labelling, PCR 101
 End labelling DNA size markers 103
 End labelling of oligonucleotide probes 101
Endogenous enzyme 21
Endogenous oxidation blocking solution 6, 10
Enzyme
 digestion 43, 65, 113, 119
 entrapment 18
Enzyme histochemistry 182

flash freezing 200
sectioning 200
staining 201
troubleshooting 200

ENZYME HISTOCHEMISTRY OF SKELETAL MUSCLE 161

Eosin stain 184
Eosin-65 stain 222, 226
Epitopes 1
Esterase 176
Ethanol fixation 15
Ethidium bromide 92, 133
ethidium bromide staining 78
interpreting ethidium bromide-stained gels 94
Excitation spectrum 133
Extraction buffer, PCR reagent 82, 83
Extraction of DNA from formalin-fixed, paraffin-embedded tissue 81

F

F-1,6-di-P incubation medium, skeletal muscle stain reagent 191
F-6-P incubation medium, skeletal muscle stain reagent 192
False-negative results
immunohistochemistry 20
PCR 85
False-positive results
immunohistochemistry 17, 18, 21
PCR 85
Fc receptors 21
Feulgen reaction 131
classical 136
azure A 139
thionin 141
acriflavine 143
histogram 135
FFPE, formalin-fixed, paraffin-embedded 81
Fiber types, skeletal muscle 161
Filters, cytopathology techniques
Gelman 212
millipore 212
nucleopore 212
Fine-needle aspirations 207
5' End-Labeling Kit, PCR 103
Fixation of smears 209
Flash freezing of muscle biopsy tissue 163, 200
Floaters, cytopathology preparation problem 225
Flow cytometry
count of nuclei 119

L

data collection 134
deparaffinization 118
fluorescence cytometry 133
instrumentation 133
isolation and staining of mononuclear cells from whole blood 126
isolation and staining of nuclei from fresh tissue 125
propidium iodide staining of nuclei 120
protease digestion 119
quality control 127
rehydration 118
tissue sectioning 118
troubleshooting 123

Flow histogram
diploid cell population 112
diploid plus aneuploid 112

Flow-cytometric analysis 113

Fluorescence cytometry 133

Fluorescence staining methods 149

- Acriflavine 150
- Acridine orange 152
- Propidium iodine 120, 154
- DAPI 120

Fluorescence intensity 113

Fluorescent compounds 14

Fluorimetry 133

Fluormount, slide mounting medium 144

Fluorochromes 131, 133, 149

Formalin-fixed, paraffin-embedded (FFPE) 81

Formalin-saline 187

Formamide 42

- formamide solution 46
- formamide solution, ultrapure 61

Freezing artifacts, muscle biopsies 200

Fresh tissue, flow cytometry preparation 123

G

G0-G1 113, 134
G2-M 113, 134
Gallocyanine-chrome alum 132, 145, 147
Gel electrophoresis 78, 92
Gel loading buffer 92
Gel/Mount, slide mounting medium 144, 152, 155
Gelman filters 212
Gene amplification, detection of 77
Gene mutation, detection of 77
Gene rearrangement, detection of 77

Giemsa stain **230**
Gill's hematoxylin **8, 27**
Glass microcarrier beads, in situ hybridization slide preparation **44, 47**
Glutaraldehyde fixation **15**
Glycerol gelatin, slide mounting medium **178, 181, 192, 198**
Glycogen **188**
Gold particles, immunohistochemistry **14**
Gomori's trichrome stain **182**
Gram's iodine, skeletal muscle stain reagent
 (IKI) stock solution **189**
 glycerin **189**
Gum tragacanth, muscle biopsy preparation **164**

H

Hank's balanced salt solution (HBSS) **115**
Haptens **1**
HCl, 5N **136**
Heating block **44**
Hemacytometer **114, 126**
Hematoxylin **221, 182, 184**
 Gill's hematoxylin **182**
 Harris' hematoxylin **198**
 Mayer's hematoxylin **49, 63, 194**
Hematoxylin and eosin for frozen sections **184**
Hemo-De, clearing agent **115**
Histones **42**
Histopaque 1077 **126**
Horseradish peroxidase (HRP) **3, 43**
Hot-start, PCR **90**
Human leucocyte antigen (HLA) **1**
Humidity chamber **6, 9, 10**
 staining rack **10**
Hybridization **41, 43, 78, 98**
 hybridization mixture **47, 62**
 hybridization procedure **49, 64**
Hydrochloric acid bath **222**
Hydrogen peroxide **3, 10, 46**

I

Idiotype **2**
Image cytometry **131**
 quantitative staining techniques **131**
Image-analysis video system **133**
Imidazole, DAB stain enhancer **60, 63**
Immunogen **2**
Immunoglobulin Fc receptors **21**

L

- IMMUNOHISTOCHEMISTRY: ANTIGEN DETECTION IN TISSUE 1
Avidin-Biotin Complex Method (ABC) 8
Peroxidase-antiperoxidase method (PAP) 12
IN SITU HYBRIDIZATION (ISH) 41
In Situ Hybridization of Viral Inclusions 41
Interphase Cytogenetics in Paraffin Sections by In Situ Hybridization 58
In Situ Hybridochemistry (ISHC) 59
Incubation medium and solutions, skeletal muscle stain reagents 176, 178, 186, 191, 192
Instrumentation, image cytometry
photomultiplier 133
scanning microspectrophotometers 133
video systems 133
Insulin solution, skeletal muscle stain reagent 188, 189
Intermyofibrillar material, skeletal muscle stain result 183
Interphase cytogenetics 58
Interphase Cytogenetics in Paraffin Sections by In Situ Hybridization 58
Inventory control, immunohistochemistry laboratory 25
ISH (In Situ Hybridization) 41
ISH Dry Method 65
ISH Wet Method 66
ISHC (In Situ Hybridochemistry) 59
Isolation and staining of mononuclear cells from whole blood 126
Isolation and staining of nuclei from fresh tissue 125
Isopentane (2-methyl butane), muscle biopsy freezing 164, 165

J

- JC virus probe 44

K

- Kappa light chain 2
KCl, 1M, PCR reagent 81
Kinase 101
Kinase buffer 102, 104

L

- Laboratory organization, immunohistochemistry 23
Laking 18
Lambda light chain 2
Liquid nitrogen 164
List of reagent antibodies (Appendix 2), immunohistochemistry 30
Lymphocyte control, image cytometry 134
Lysate 83

M

- Magnesium, optimization of concentration **86**
Magnesium sulfate, 0.1M, skeletal muscle stain reagent **178**
Mayer's hematoxylin **49, 63, 194**
Melanin **115**
 bleaching of **115**
Membrane blocking solution (MBS), PCR reagent **98**
Membrane filters **211**
Metachromatic stain **153**
Methyl green **14, 17**
Microspheres, flow cytometry instrument standard **127**
Microtome
 decontamination **82**
 knives **166**
Microwave oven **15, 59**
 Microwave slides **64**
Millipore filters **212**
Mitochondria **169**
Modified Gomori's trichrome stain, skeletal muscle stain **182**
Monoclonal antibodies **2, 19, 25**
Muscle **161**
 biopsies **161**
 fiber type 1 and type 2 **161**
 sectioning **166**
 staining precautions **166**
Mutation, detection of **77**
Myelin of the nerve branches, skeletal muscle stain result **183**
Myoadenylate deaminase, skeletal muscle stain **180**
Myofibrils, skeletal muscle stain result **183**

N

- NADH (NADH diaphorase), skeletal muscle stain **168**
NADH staining solution, skeletal muscle stain reagent **169**
Naphthol **176**
Negative control
 immunohistochemistry **25**
 PCR **82**
Neutral buffered formalin **132, 178**
Nitro-BT solution, skeletal muscle stain reagent **168, 180, 186, 191**
Nonfat dry milk, 5% **61**
Nongynecologic samples **225**
Nonspecific binding, immunohistochemistry **18**
Nonspecific reaction, immunohistochemistry **17**
Nonspecific esterase, skeletal muscle stain **176**
Normal hydrochloric acid solution, skeletal muscle stain reagent **193**

L

Normal population, image cytometry 134
Normal serum, immunohistochemistry 7, 9, 27
Nuclear fluorescence 111
Nucleic acids 42
Nucleopore filters 212
Nucleotides 77
Nylon membrane, PCR 97

O

Oil red O in propylene glycol, skeletal muscle stain and reagent 198
Oligonucleotide, PCR
 primers 101
 probes 101
Optimizing PCR for a specific application 84
Orange G stain 222, 226
Osmium tetroxide solution, skeletal muscle stain reagent 196
Osmium tetroxide-p-phenylenediamine lipid stain 196
Overdigestion, immunohistochemistry 18

P

PAP (Papanicolaou) smears, cytopathology techniques 207, 210
PAP (peroxidase-antiperoxidase) technique,
 immunohistochemistry procedure 12, 18
Papanicolaou 208, 225
Papanicolaou staining technique 208, 221
 quality control 226
 staining technique for filters 224
 destaining of slides 227
Para-phenylenediamine, (p-Pd), skeletal muscle stain reagent 196
Paraffin negative control, PCR 82, 83, 85
Pararosaniline 132, 176
Pararosaniline stock 176
PBS (phosphate buffered saline) 6, 21, 45, 61, 66, 116
 PBA 116
 PBSE (1X) 45
PCR See polymerase chain reaction
Performance testing, immunohistochemistry 24
Periodic acid-Schiff reaction (PAS), frozen sections 193
Periodic acid solution, 0.5%, skeletal muscle stain reagent 193
Permount, slide mounting medium 6, 14, 27, 63
Peroxidase-antiperoxidase method for antigen detection 12
Peroxidase-like, immunohistochemistry 17
Phenol/chloroform/isoamyl alcohol, PCR reagent 103
Phi-X DNA, PCR standard 103

Phosphate buffer **147, 168**
phosphate buffer, 1/15M **230**
phosphate buffer, 0.1M **6**
phosphate buffer, 0.2M **186**
phosphate buffer, pH 6.8 **145**
phosphate buffer with Triton X-100 **145**
Phosphate buffered saline (PBS) **45, 61, 116**
phosphate buffered saline, 0.01M **6**
Phosphofructokinase (PFK), skeletal muscle stain reagent **191**
Phosphor particles, fluorescence cytometry standard **133**
Phosphorylase (amylophosphorylase), skeletal muscle stain **188**
phosphorylase solution **189**
Photomultiplier tube **134**
PI **See propidium iodide stain**
Plasma cell **2**
Ploidy **120**
aneuploid **134**
diploid **134**
euploid **134**
tetraploid **134**
Poly-L-lysine **8, 44**
Polyclonal antisera **2, 19, 24**
Polymerase, PCR
DNA **77**
Taq **78**
POLYMERASE CHAIN REACTION 77
Polymerase chain reaction (PCR) **77, 88, 90**
avoidance of contamination **80**
buffer **89**
controls **84**
hot start **90**
optimization **85**
protocol **88**
uses of **77**
Polymorphonuclear leukocytes (PMNs) **225**
Polystyrene sphere, fluorescence cytometry standard **133**
Positive control
immunohistochemistry **25**
PCR **85, 94**
Posthybridization wash, *in situ* hybridization **48**
Potassium chloride, 3M, skeletal muscle stain reagent **180**
Preparation of cytology samples **210**
PREPARATION OF NUCLEI FOR FLOW CYTOMETRY 111
Primary antibody **3, 4, 7, 24, 27**
Primers, PCR **78**
concentration **86**
design **84**

temperature 80, 86
Probes
 biotin-labeled DNA probe 43
 DNA probe 43
 end-labelling of oligonucleotide probes 101
 JC virus probe 44
 probe mixture 62
 use of radioactively labelled 78, 96, 98
Procedure for filters, cytopathology technique 224
Proliferative cells 113
Propidium iodide 111, 133, 154
Propidium iodide stain 116, 117, 120, 122
Propylene glycol, skeletal muscle stain reagent 198
Protease digestion
 in situ hybridization 43
 PCR 81
 flow cytometry 115, 119
Proteinase K 43, 46, 59, 65, 81
Proteolytic digestion solution, immunohistochemistry 6, 8
Proteolytic enzyme 113
Purine-deoxyribose bonds 136

Q

Quality assurance, PCR 80
Quality control
 immunohistochemistry 25
 flow cytometry 127
QUANTITATIVE STAINING TECHNIQUES FOR IMAGE CYTOMETRY 131

R

Radioactive probe 79
Radioactive waste 99
Rapid gallocyanine-chrome alum stain 147
RATPase (reversal of adenosine triphosphatase), skeletal muscle stain 173
Reactive aldehyde groups 132, 136
Reagents, immunohistochemistry 24
Reagent antibodies, list of 30
Replication, in situ hybridization 42
Reporter molecule, immunohistochemistry 2
Results, PCR
 false-negative, false-positive 85
Ringer's solution, skeletal muscle stain reagent 168
Rinsing solution, skeletal muscle stain reagent 181
RNA 58

RNAse 132, 145, 152, 154

 stock solution 116

 working solution 116

Romanovsky stain 208, 230

S

S-phase 113, 134

 S-phase, DNA-histogram 113

Saccomanno method for preparation of sputa 214, 215, 225

Saline sodium citrate (SSC) 45, 61

Scanning microspectrophotometers 133

Schiff's leuco-fuchsin solution 193

Schiff's reagent 132, 136

SDH (Succinic dehydrogenase), skeletal muscle stain 186

SDS (Sodium dodecyl sulfate) 45

Secondary antibody, immunohistochemistry 3, 4, 7

Sectioning, muscle biopsies 166, 200

Sensitivity, immunohistochemistry 18

Serial dilution, immunohistochemistry 23

Shaking water bath, in situ hybridization 59

Signal-generating system, in situ hybridization 43

Silane

 Silane solution 60

 Silane-coated glass slides 59

Single-stranded DNA (ssDNA) 42, 78

Single-stranded genomic DNA 41

Single-stranded probe DNA 41

Skeletal muscle 161

Slide preparations of cytology samples 210

SO₂ water, Feulgen stain reagent 137

Sodium acetate, 3M 103

Sodium barbital, skeletal muscle stain reagent 170, 173

Sodium dodecyl sulfate (SDS) 45

Sodium nitrite, skeletal muscle stain reagent 176

Sodium phosphate 176

Soft blocks, muscle biopsy preparation problem 200

Southern blot 96

 blotting 97

 denaturing solution 97

 hybridization 98

 interpreting autoradiograms 99

 washing 98

 washing solution 97

Specific, immunohistochemistry

 analyte 2

 reaction 17

L

testing **24**
Spermidine, PCR reagent **104**
Spinal tap needle **121, 124**
Spray fixatives, cytopathology techniques **209**
Square Bio-Assay culture dishes **59**
SSC (saline sodium citrate) **45**
ssDNA, single-stranded DNA **42**
Staining methods for absorption cytometry **136**
Staining methods for fluorescence cytometry **149**
Stock barbital solution, skeletal muscle stain reagent **171, 174**
Storage of compounds, immunohistochemistry **24**
Streptavidin **43**
Succinic acid, 0.2M, skeletal muscle stain reagent **186**
Succinic dehydrogenase (SDH), skeletal muscle stain **186**
Synthesis phase **113**

T

T-cell lymphocytes **1**
T4 polynucleotide kinase enzyme **101, 102, 104**
Taq DNA polymerase **78, 90**
Target, PCR
 DNA **78**
 gene **85**
 sequence **78, 79**
Target fibers, skeletal muscle result **169**
TBE, 10 X, PCR reagent **92**
Tearing, bunching, or compression, muscle biopsy preparation problem **200**
Tetraploid **134**
Thermal cycler **78, 87, 88**
 programming **87**
Thimerosol, antibacterial solution **61**
Thionin **132**
Thionin Feulgen stain **141**
Tissue, fresh, flow cytometry preparation **123**
Titration, immunohistochemistry **7**
Toluidine blue test **211, 213**
Trichrome stain, modified Gomori's **182**
Tris buffer
 Tris buffer, 0.05M **46**
 Tris buffer, 0.1M **60, 115**
 Tris buffer, 0.5M **81, 88**
 Tris buffer, 1M **103**
 Tris buffer, 1.5M **102**
Triton X-100 **21, 145, 153**
Triton-PBA **116**
Troubleshooting **20**

ISH 52, 67
flow cytometry 123
histochemistry of skeletal muscle 200
PCR
 electrophoresis 94
 hybridization 99
 lysate preparation 83
 PCR 90
Tubular aggregates, skeletal muscle stain result 169

U

Ultralow freezer 163
Unbranched amylase-type polysaccharide, skeletal muscle 188
Unfixed specimens 209
Upper buffer mix 91
Uranyl glass 133

V

Video systems 133, 134
Viral pathogens, detection of 77
Vortex Genie 59

W

Wash solution, posthybridization, in situ hybridization 63
Water bath 27
Working iodine solution, skeletal muscle stain reagent 189

X

Xylene cyanol, PCR reagent 94

Z

ZnCl₂, 100mM, PCR reagent 104

L

Manual of
HISTOLOGIC STAINING METHODS
of the
Armed Forces Institute of Pathology



Third Edition

American Registry of Pathology
Lee C. Lumm (Editor)

**Manual of
HISTOLOGIC STAINING METHODS
of the
Armed Forces Institute of Pathology**

Third Edition

**NATIONAL SCIENCE LIBRARY
NATIONAL RESEARCH COUNCIL**

Manual of
HISTOLOGIC STAINING METHODS
of the
Armed Forces Institute of Pathology

Third Edition

Edited by

LEE G. LUNA, HT (ASCP)

Chief, Histopathology Laboratories,
Armed Forces Institute of Pathology

The Blakiston Division

McGRAW-HILL BOOK COMPANY

New York Toronto London Sydney

General References in Histopathologic Technique

BOOKS

- Baker, J. R.: "Principles of Biological Microtechnique," John Wiley and Sons, Inc., New York, N. Y., 1958.
- Barka, T., and P. J. Anderson: "Histochemistry: Theory, Practice, and Bibliography," Hoeber Medical Division, Harper and Row, Publishers, Inc., New York, N. Y., 1963.
- Conn, H. J.: "Biological Stains," 7th ed., The Williams and Wilkins Company, Baltimore, Md., 1961.
- Gurr, E.: "Encyclopedia of Microscopic Stains," The Williams and Wilkins Company, Baltimore, Md., 1960.
- Gray, P.: "The Microtomists Formulary and Guide," McGraw-Hill Book Company, New York, N. Y., 1954.
- Humason, G. L.: "Animal Tissue Techniques," W. H. Freeman and Company, San Francisco, Calif., 1962.
- Lillie, R. D.: "Histopathologic Technic and Practical Histochemistry," 3rd ed., McGraw-Hill Book Company, New York, N. Y., 1965.
- Mallory, F. B.: "Pathological Technique," Hafner Publishing Co., New York, N. Y., 1961.
- McManus, J. F. A., and R. W. Mowry: "Staining Methods: Histologic and Histochemical," Hoeber Medical Division, Harper and Row, Publishers, Inc., New York, N. Y., 1963.
- Pearse, A. G. E.: "Histochemistry: Theoretical and Applied," 2nd ed., Little, Brown and Co., Boston, Mass., 1960.
- Preece, A.: "A Manual for Histologic Technicians," 2nd ed., Little, Brown and Co., Boston, Mass., 1965.
- Thompson, S. W.: "Selected Histochemical and Histopathological Methods," Charles C Thomas, Publishers, Springfield, Ill., 1966.

JOURNALS

- American Journal of Medical Technology*, Suite 1600, Herman Professional Bldg., Houston, Tex. 77025
- Journal of Histochemistry and Cytochemistry*, The Williams and Wilkins Co., 428 East Preston St., Baltimore, Md. 21202
- Laboratory Investigation*, The Williams and Wilkins Co., 428 East Preston St., Baltimore, Md. 21202
- Stain Technology: A Journal for Microtechnic and Histochemistry*, The Williams and Wilkins Co., 428 East Preston St., Baltimore, Md. 21202

Contents

<i>Foreword</i>	V
<i>Preface</i>	VII
<i>General References</i>	IX
1 Preparation of Tissues	1
Fixation; Decalcification; Keratin and Chitin Softening Procedures	
2 Processing of Tissue	12
Dehydration, Clearing, Impregnation and Embedding; Processing Schedules; Double Embedding; Carbowax Method	
3 Preparation of Sections	21
Care and Use of Microtome Knives; Hints on Sectioning; Block Orientation; Soaking; Floating, Separating, and Picking Up Sections; Section Adhesives; Frozen Sections	
4 Routine Staining Procedures	32
Hematoxylin and Eosin Stains; Hematoxylin Solutions; Eosin Solutions; Hematoxylin and Eosin Methods; Removal of Pigments and Precipitates; Restoration of Basophilic Properties; Removal of Cover Slips; Labeling for Permanent Filing	
5 Special Techniques	47
Processing Human Temporal Bones; Paraffin Technique for Eyes; Trypsin Digestion for Retinal Vessels; Staining of Retinal Vessels; Sectioning Undecalcified Tissues; Paraffin Method for Large Bones and Whole Organs; Methods for Oral Tissues; Celloidin Methods; Routine Celloidin Staining; 35mm Film Method; Plastic Film Methods; Multiple Staining on One Slide; Pannicolaou Method for Smears	
6 Methods for Connective Tissue	72
Basement Membrane; Bile Canaliculi; Collagen; Fibrin; Keratin, Prekeratin, and Mucin; Muscle; Elastic Tissue; Reticulum	
7 Methods for Cytoplasmic Granules	100
Argentaffin Granules; Golgi Apparatus; Juxtaglomerular Granules; Pancreatic Islet Cells; Chromaffin; Pituitary Cells; Mast Cells; Spermatozoa	
8 Methods for Hematologic and Nuclear Elements	119
Bone Marrow; Hemofuchsin; Hemoglobin; Hemosiderin; Malaria Parasites; Mitochondria; Nucleic Acids; Polychromasia; DNA Digestion; RNA Digestion; Sex Chromatin	

9 Methods for Fats and Lipids	140
Cholesterol; Free Fats; Fatty Acids; Fat in Frozen Sections; Fat in Paraffin Sections; Lipids; Phospholipids; Pyridine Extraction; Unsaturated Lipids, Active Carbonyl Groups	
10 Methods for Carbohydrates and Mucoproteins	153
Amyloid; Glycogen; Alcoholic Hyalin; Mucin; Metachromasia; Mucosubstances, Acid Mucopolyaccharides; Diastase Digestion; Hyaluronidase Digestion; Sialidase Digestion; Miscellaneous Polysaccharides	
11 Methods for Pigments and Minerals	174
Bilirubin; Calcium; Calcium Oxalate; Copper; Hemosiderin; Iron; Lipofuchsin; Urate Crystals	
12 Methods for Nerve Cells and Fibers	189
Astrocytes; Nerve Fibers; Axon Terminals; Axis Cylinders and Dendrites; Nerve Endings; Glia Fibers; Myelin; Negri Bodies; Nissl Substances; Motor End Plates; Nerve Cell Products	
13 Methods for Bacteria, Fungi, and Inclusion Bodies	217
Acid Fast Organisms; Gram Positive and Gram Negative Bacteria; Amoeba; Fungi; Amniotic Fluid Embolism; Inclusion Bodies; Rickettsia; Spirochetes	
Artifacts	241
Index	253

Chapter 1

Preparation of Tissue

FIXATION

The foundation of all good histological preparations is adequate and complete fixation. Fixation is required to (1) *prevent* post mortem changes such as putrefaction and autolysis; (2) *preserve* various cell constituents in as life-like manner as possible; (3) *protect* by hardening the naturally soft tissue, thereby allowing easy manipulation during subsequent processing; (4) *convert* the normal semi-fluid consistency of cells to an irreversible semi-solid consistency; (5) *aid* in the visual differentiation of structure by application of biological dyes and chemicals. To accomplish these objectives the tissue should be placed in the fixative immediately upon removal from the body or as soon after death as possible.

The choice of fixing agent should be determined by the purpose for which the tissue is to be stained or preserved.

Blocks should be cut thin enough so that the fixative will penetrate the tissue within a reasonably short time. To this end the block should not be more than 4mm in thickness and should be immersed in at least ten times its volume of fixative.

Ten percent buffered neutral formalin is the most widely used fixative because it is compatible with most stains. The length of time for fixation depends upon the size of the block and fixative used. It is well to have a clear understanding of the effects of fixation, the time required for complete fixation of specific tissues, and the post fixation handling of tissue specimens.

That many specimens may be ruined, by poor handling subsequent to proper fixation, has been proven. This generally occurs when one fails to realize that different fixatives require varied times to effect complete fixation; and the specimen may require a particular treatment, immediately following fixation, to insure retention of specific staining properties.

Additional useful knowledge, is the action of a simple fixative on different parts of the tissue specimen. A partial list of the characteristics of certain common simple fixatives and their various effects follows, while more detailed information in this regard can be found in: Baker, J. R.: *Principles of Biological Microtechnique*, New York, John Wiley & Sons, Inc., 1958.

CHARACTERISTICS OF CERTAIN AGENTS USED AS FIXATIVES

FORMALDEHYDE, 10% FORMALIN

FORMALDEHYDE, Gas. Formaldehyde is a flammable colorless gas at ordinary temperatures having a pungent suffocating odor. It is very soluble in water (up to 55%) and also is soluble in both alcohol and ether. A very reactive reagent, it combines readily with many substances and polymerizes easily.

FORMALDEHYDE, Solution (Formalin, Formol). A solution of about 37% by weight, of formaldehyde gas in water, usually with 10 – 15% methanol added to prevent polymerization. This solution is the same strength as that known as Formalin 40%.

Chapter 2

Processing of Tissue

DEHYDRATING, CLEARING, IMPREGNATING, AND EMBEDDING

A specimen brought to the laboratory is usually marked with an identifying number or name. Keep this identification with the specimen throughout processing. All identifying marks should be made with a soft lead pencil. Do not use ink or wax pencils.

The surface from which sections are to be cut may be indicated by notching the opposite surface, or by marking it with India ink. An indelible lead pencil may also be used for this purpose. When the tissue is embedded in paraffin, the marked surface of the block is uppermost.

Fixed tissues must be maintained in position by a firm medium so that thin, uniform sections, can be cut. Media suitable for this purpose are paraffin, celloidin, and carbowax.

Processing by the paraffin technic is accomplished most rapidly and gives the best results when thin sections of soft tissue are desired. Since paraffin is not miscible with water, the tissue must be dehydrated and then cleared in solutions miscible with paraffin before impregnation.

Well processed tissue is achieved by a step by step infiltration of the required reagents each preparing the tissue for the one to follow, so that the end result will be a section closely resembling the living state of the specimen. Every cell should be recognizable as to type, enabling the pathologist to focus all his attention on the cell pattern which determines the diagnosis. Properly fixed tissue is essential, as the following steps of processing build upon it.

It is always advisable to remove fixatives before processing. For various methods note remarks under each fixative in Chapter 1.

Dehydration is the removal of all extractable water by a dehydrant diffusing through the tissue, and in the process diluting itself 2 – 4%. Some dehydrants used are tetrahydrofuran, acetone, dioxane, isopropyl alcohol, and ethanol.

Alcohol is the most commonly used dehydrant usually starting with 80%. Exceptions to this are when processing tissue with cavities, cysts, and embryos, which will have less shrinkage and distortion when started in 60%. Compact or fibrous tissue, such as muscle, brain, lymph nodes, and glands infiltrate more rapidly and completely in the 60%, especially when vacuum is employed. Allow sufficient time in the starting alcohol for complete infiltration of the tissue. The dehydration process continues by upgrading the alcohols to absolute alcohol. Isopropyl alcohol can be used as a substitute for absolute alcohol if necessary, but absolute alcohol is always preferred. Note. Isopropyl alcohol should not be used to dissolve dyes and reagents until it has been tested for each use against absolute alcohol.

Acetone provides a rapid method, used sometimes in hospital laboratories, and when required as a "stat" method. The low cost is an asset, but shrinkage and distortion plus a subsequent dryness and hardness which causes cutting problems, are disadvantages to its use.

Chapter 3

Preparation of Sections

CARE AND USE OF MICROTOME KNIVES

The cutting of good sections depends greatly upon practical experience and a complete thorough knowledge of the equipment used. Manual dexterity is a *must*; without it one may face a difficult task in handling the fine manipulative detail required in section cutting. Hurried and inadequate introductory and/or initial training will reflect badly for years afterward; conversely a high standard of training will prevail admirably throughout one's career. *Speed* in performing any phase of histologic technique should *never* be a primary objective since it only leads to unsatisfactory processing, cutting, and staining of the tissue sections. A well trained tissue technician will produce first rate sections in a far shorter time than one who always is aiming primarily at speed.

Since the results produced by histologic technique depend greatly upon the knives used to cut the sections, it is imperative that each technician know how to care for his knife as well as how to use it. A perfect edge on a microtome knife is difficult to describe, however, with a good knife edge, sections of 3 microns in thickness should easily be cut from well-processed, average-sized, tissue blocks. The sections should ribbon off the block in a flat unwrinkled fashion, much as paper comes off a printing press. Microscopically, the section must show no vertical lengthwise scratches or horizontal thick and thin areas. (see Artifacts, page 247). For problems and possible causes in cutting see Fig. 4.

Knife sharpening can be accomplished by mechanical means on one of several kinds of commercial knife sharpeners. However, in the absence of such assistance, it should not be difficult to acquire the skill and ability to keep one's knife in a satisfactory condition using the hand-honing method. The quality of the section produced, more than compensates for the time spent in learning to keep, and in keeping, a knife properly sharpened.

In hand-honing, naturally, good quality stones give the best results. They are expensive, but only the best should be used. The finer the grain in a hone the harder the stone. The yellow Belgian and the Belgian black vein are the finest available anywhere and are, therefore, highly recommended. It is best to purchase a combination hone: Belgian yellow vein and Belgian black vein, mounted back to back.* A liquid medium for sharpening with a hone is necessary, such as household 3 in 1 oil, mineral oil, vegetable oil, or a neutral soap solution. The choice must be left to the technician. At the Armed Forces Institute of Pathology, the neutral soap solution is used because it can be made readily by dissolving household (bar) soap in water.

While honing, the knife should be kept flat, held to the hone by its own weight, with its edge facing the direction of the "heel to toe" motion, under continuous but light pressure (Fig. 5).

*Microtome Knife Hone - Yellow Belgian, Fisher Scientific Co., 7722 Fenton St., Silver Spring, Md. 20910

Chapter 4

Routine Staining Procedures

HEMATOXYLIN AND EOSIN STAINS

Hematoxylin, a natural dye which was first used about 1863, is without doubt the most valuable staining reagent used in histologic work. It has little affinity for tissue when used alone but in combination with aluminum, iron, chromium, copper or tungsten salts it is a powerful nuclear stain. It has polychromatic properties which may be brought out with the proper differentiation. The active coloring agent, hema-tein, is formed by the oxidation of hematoxylin. This process known as "ripening" takes several days, or weeks, unless it is hastened by the addition of an oxidizing agent such as mercuric oxide, hydrogen peroxide, potassium permanganate, sodium perborate, or sodium iodate. These artificial oxidizers only start the process, so that the solution can be used immediately, but this oxidation process continues slowly over a period of time, during which the hematoxylin retains its staining properties. Once oxidation is complete, the hematoxylin is no longer useful for staining. By increasing the amount of the oxidizing agent the process is much more rapid, thus decreasing the life of the stain so that the amount listed for a given formula should be closely observed. Storage is another factor that has an effect on oxidation. When stored in a dark, tightly sealed container the process is slower, but when in staining dishes exposed to light and air it is markedly increased, therefore, in a staining setup, the solution should be changed at least once a week for consistent staining results.

The most common formulas for staining with hematoxylin are the combinations with aluminum in the form of alum. Those in general use were formulated by Harris, Mayer, Delafield, Ehrlich, Bullard and Bohmer. Sections stained with alum hematoxylins may be counterstained with Eosin, Safranin, Phloxine or other contrasting stains.

The hematoxylins that are combined with iron and tungsten also have their uses. Iron hematoxylin is used in staining myelin and as a nuclear stain in many of the trichrome and other special stain procedures. The one used most extensively in our laboratory was formulated by Weigert. Mallory's phosphotungstic acid hematoxylin (PTAH) is also often used, however not as a nuclear stain.

Although the hematoxylin and eosin stain has been used for nearly a hundred years, a few words of admonition concerning the stain are in order. The word "routine," as applied to the hematoxylin and eosin procedure, should not be used in this connection for Webster defines "routine" as a regular, more or less unvarying procedure. Any one that has worked with the H&E stain knows that many factors contribute to cause some variation in this technic. Examples of this could be: the fixative used, the fixation exposure time, age of staining solution, etc. Therefore, we should not allow the term "routine" to cause the normal amount of laxness usually associated with it.

There are two methods of staining when hematoxylin is employed: Progressive and Regressive.

Chapter 5

Special Techniques

PROCESSING HUMAN TEMPORAL BONES

We are pleased to include in this new edition of histological staining techniques the unaltered procedure for processing human temporal bones. This information was made available to the AFIP by Dr. Stacy R. Guild, Emeritus Associate Professor of Otology of the Johns Hopkins University School of Medicine. A procedure used by Dr. Guild after fifty years experience with human temporal bone histopathology, it is designed to minimize technical artifacts. It represents the distillation of knowledge after experimenting with more than 40 separate histological procedures for human temporal bones. The delicate inner ear membranes require the most careful technical handling to prevent tearing or distortion. The AFIP is grateful to Dr. Guild for making this information available.

INTRODUCTION

The petrous portion of the temporal bone is the housing of the inner and middle ear structures, as well as containing other important tissues such as part of the carotid artery and the facial nerve. Specimens taken for study of the middle ear and inner ear structures should include bone anterior to the internal auditory meatus and posterior into the mastoid region. Between these two landmarks, the desired structures will be found. The specimen block may be removed by making a first cut perpendicular to the tentorial attachment anterior to the internal auditory meatus and a second cut perpendicular to the tentorial attachment 1-1/2 inches postero-lateral to the first. These cuts, if extended 3/4 inch anterolaterally and inferiorly, will contain all of the middle ear and inner ear specimens.

PROCEDURE

1. Place fresh bone specimens in 20% formalin for one hour. Then change to fresh 20% formalin. Tip to allow trapped air to leave the mastoid and other air spaces. Tip slowly, several times, using glass rods or forceps to handle the specimen.

2. Fix in 20% formalin for 24 hours.

Use degassed water to dilute stock formalin. Degassed water is used in order to prevent bubbles from forming on the surfaces of the bone or within the labyrinth. Water may be degassed by subjecting water to a vacuum from a faucet aspirator or a pump for a few hours. Use a thick-walled flask which will withstand the vacuum. For a small number of temporal bones, a 1-liter amount will suffice daily; a 2-gallon jar will be required for large daily usages. After degassing, disconnect slowly from the vacuum; a rapid disconnection will agitate the water with bubble formation. When using the water, transfer by siphon so that it mixes with air as little as possible.

400 ml of fixative is adequate for a pair of bones. In a pint jar add 80 ml of formalin (a 40% solution of formaldehyde in water) to 320 ml of degassed water. Use a tall pint glass fruit jar with glass lid sealed by a rubber ring for each pair of bones. The pair should be kept together.

Chapter 6

Methods For Connective Tissue

LILLIE'S ALLOCHROME METHOD FOR CONNECTIVE TISSUE

FIXATION. Any well fixed tissue.

TECHNIQUE. Cut paraffin sections at 6 microns.

SOLUTIONS

SCHIFF REAGENT SOLUTION

(See page 159)

0.5% PERIODIC ACID SOLUTION

Periodic acid	0.5 gm
Distilled water	100.0 ml

0.5% SODIUM METABISULFITE SOLUTION

Sodium metabisulfite	0.5 gm
Distilled water	100.0 ml

WEIGERT'S IRON HEMATOXYLIN SOLUTION

(See page 35)

PICRIC ACID-METHYL BLUE SOLUTION

Picric acid, saturated aqueous	100.0 ml
Methyl blue	40.0 mg

STAINING PROCEDURE

1. Deparaffinize and hydrate to distilled water.
2. Periodic acid solution for 10 minutes.
3. Wash in tap water for 5 minutes.
4. Schiff's reagent solution for 10 minutes.
5. Sodium metabisulfite solution for two changes, 2 minutes each.
6. Wash in tap water for 10 minutes.
7. Weigert's iron hematoxylin solution for 2 minutes.
8. Wash in tap water for 10 minutes.
9. Picric acid-methyl blue solution for 6 minutes.
10. Dehydrate in 95% alcohol, absolute alcohol, and clear in xylene, two changes each.
11. Mount with Permount or Histoclad.

Chapter 7

Methods For Cytoplasmic Granules

DIAZO METHOD FOR ARGENTAFFIN GRANULES

FIXATION. 10% buffered neutral formalin.

TECHNIQUE. Cut paraffin sections at 6 microns.

SOLUTIONS

1% BRENTAMINE FAST RED B SOLUTION (STOCK)

Brentamine Fast Red B*	1.0 gm
Distilled water	100.0 ml
Keep at 4-5°C.		

LITHIUM CARBONATE SOLUTION (STOCK)

Lithium carbonate	1.36 gm
Distilled water	100.0 ml
Keep at 4-5°C.		

BRENTAMINE FAST RED B SOLUTION (WORKING)

Brentamine Fast Red B (Stock)	5.0 ml
Lithium Carbonate (Stock)	2.0 ml
Mix and let stand for 6-8 minutes at 4-5°C before use.		

MAYER'S HEMATOXYLIN SOLUTION

(See page 33)

STAINING PROCEDURE

1. Deparaffinize and hydrate to distilled water.
2. Brentamine working solution at 4-5°C for 40 to 60 seconds.
3. Rinse in distilled water, two changes.
4. Mayer's hematoxylin solution for 3 minutes.
5. Blue in warm tap water for 5 minutes.
6. Rinse in 95% alcohol, two changes.
7. Dehydrate rapidly in absolute alcohol, then clear in xylene, two changes each.
8. Mount with Permount or Histoclad.

RESULTS

Argentaffin granules	- rust red
Background	- yellow
Nuclei	- blue

*Roboz Surgical Instrument Co., 810-18th Street, N.W., Washington, D.C. 20006

Chapter 8

Methods For Hematologic And Nuclear Elements

WOLBACH'S GIEMSA METHOD

FIXATION. Zenker's or other well-fixed tissues.

TECHNIQUE. Cut paraffin sections at 6 microns.

SOLUTIONS

GIEMSA* SOLUTION (STOCK)

Giemsa powder	1.0 gm
Glycerin	66.0 ml
Alcohol, methyl	66.0 ml

Mix glycerin and Giemsa powder. Place in a 60°C oven for 2 hours. Finally add the 66 ml methyl alcohol.

GIEMSA SOLUTION (WORKING)

Giemsia solution (stock)	1.25 ml
Alcohol, methyl	1.5 ml
Distilled water	50.0 ml

ROSIN ALCOHOL SOLUTION (STOCK)

Rosin, white	10.0 gm
Alcohol, 100%	100.0 ml

ROSIN ALCOHOL SOLUTION (WORKING)

Rosin solution (stock)	5.0 ml
Alcohol, 95%	40.0 ml

STAINING PROCEDURE

1. Deparaffinize and hydrate to distilled water.
2. Remove mercuric chloride crystals with iodine and clear with sodium thiosulfate (see page 41).
3. Wash in running water for 15 minutes.
4. Rinse in distilled water.
5. Working Giemsa solution overnight.
6. Differentiate in working rosin alcohol solution until sections assume a purplish pink color. Check under microscope.

*Stain must be National Aniline Certified Giemsa.

Chapter 9

Methods For Fats And Lipids

SCHULTZ'S METHOD FOR CHOLESTEROL

FIXATION. 10% buffered neutral formalin.

TECHNIQUE. Frozen sections.

SOLUTIONS

2.5% FERRIC AMMONIUM SULFATE SOLUTION

Ferric ammonium sulfate	2.5 gm
Distilled water	100.0 ml

GLACIAL ACETIC-SULFURIC ACID SOLUTION

Glacial acetic acid	50.0 ml
Sulfuric acid, concentrated	50.0 ml

Add the sulfuric acid slowly, constantly stirring, to the acetic acid in a test tube or flask *cooled with ice*. *PREPARE FRESH JUST BEFORE USING.*

STAINING PROCEDURE

1. Cut frozen sections and collect in distilled water.
2. Ferric ammonium sulfate solution at room temperature for 3 days.
3. Rinse briefly in distilled water, three changes.
4. Float sections onto the slides and blot dry. Slides may be held at this point until the pathologist is ready for wet reading.
5. Place one drop of *FRESHLY PREPARED* acetic-sulfuric acid solution on the section.
6. Apply coverslip immediately.
7. Examine microscopically within a few minutes.

RESULTS

Cholesterol - green, blue-green, or blue reaction.
Background - colorless

REFERENCE. Schultz, A.: Eine Methode des mikrochemischen Cholesterinnachweises am Gewebsschnitt. *Zbl. Allg. Path.* 35:314, 1924.

OIL RED O IN PROPYLENE GLYCOL METHOD FOR FATS

FIXATION. 10% buffered neutral formalin.

TECHNIQUE. Frozen sections.

Chapter 10

Methods For Carbohydrates And Mucoproteins

BENNHOLD'S METHOD FOR AMYLOID (CONGO RED)

FIXATION. 10% buffered neutral formalin.

TECHNIQUE. Cut paraffin sections at 6 microns (see Remarks).

SOLUTIONS

1% CONGO RED SOLUTION

Congo red	1.0 gm
Distilled water	100.0 ml

1% SODIUM HYDROXIDE SOLUTION

Sodium hydroxide	1.0 gm
Distilled water	100.0 ml

ALKALINE ALCOHOL SOLUTION

Sodium hydroxide, 1%	1.0 ml
Alcohol, 50%	100.0 ml

MAYER'S HEMATOXYLIN SOLUTION

(See page 33)

STAINING PROCEDURE. Use control slide.

1. Deparaffinize and hydrate to distilled water.
2. Congo red solution for 1 hour.
3. Rinse off excess stain in water, two or three changes.
4. Differentiate in alkaline alcohol solution for 3-5 seconds. Agitate constantly until the background appears clear.
5. Wash in running water for 5 minutes.
6. Counterstain in Mayer's hematoxylin solution for 5 minutes.
7. Wash in running water for 15 minutes.
8. Dehydrate in 95% alcohol, absolute alcohol, and clear in xylene, two changes each.
9. Mount with Permount or Histoclad.

RESULTS

Amyloid	- pink to red
Nuclei	- blue

Chapter 11

Methods For Pigments And Minerals

HALL'S METHOD FOR BILIRUBIN

FIXATION. 10% buffered neutral formalin.

TECHNIQUE. Cut paraffin sections at 6 microns.

SOLUTIONS

FOUCHET'S REAGENT

Trichloroacetic acid	25.0 gm
Distilled water	100.0 ml
Mix and add:	
<u>10% Ferric chloride</u>	10.0 ml

10% FERRIC CHLORIDE SOLUTION

Ferric chloride	10.0 gm
Distilled water	100.0 ml

VAN GIESON'S SOLUTION

(See page 76)

STAINING PROCEDURE

1. Deparaffinize and hydrate to distilled water.
2. Fouchet's reagent for 5 minutes.
3. Wash in running water, then in distilled water.
4. Van Gieson's solution for 5 minutes.
5. Dehydrate in 95% alcohol, absolute alcohol, and clear in xylene, two changes each.
6. Mount with Permount or Histoclad.

RESULTS

Biliverdin	- green
Collagen	- red
Muscle	- yellow

REMARKS. Bilirubin is oxidized to biliverdin, and stains olive drab green to emerald green, depending upon the concentration of bilirubin.

REFERENCE. Hall, M. J.: *Amer. J. Clin. Path.* 34: 313-316, 1960. Copyright by Williams and Wilkins Co.

Chapter 12

Methods For Nerve Cells And Fibers

RAMON Y CAJAL'S METHOD FOR ASTROCYTES

FIXATION. Formalin ammonium bromide for 1 day at 37 °C or 10% buffered neutral formalin (see *Note*).

TECHNIQUE. Cut frozen sections at 15 to 30 microns.

SOLUTIONS

FORMALIN AMMONIUM BROMIDE SOLUTION

Formalin, 37 – 40% (Merck's blue label)	15.0 ml
Ammonium bromide	2.0 gm
Double distilled water	85.0 ml

BROWN GOLD CHLORIDE SOLUTION (STOCK)

Brown gold chloride solution (stock)	1.0 gm
Mercuric chloride solution (stock).....	100.0 ml

Solution will keep in a dark bottle for many months.

MERCURIC CHLORIDE SOLUTION (STOCK)

Mercuric chloride.....	0.5 gm
Double distilled water.....	10.0 ml

Make just before use. Dissolve bichloride of mercury by *gentle* heat.

GOLD SUBLIMATE SOLUTION (WORKING)

Brown gold chloride solution (stock)	10.0 ml
Mercuric chloride solution (stock)	10.0 ml

Mix while mercuric chloride is still warm and add 40 ml double distilled water. A precipitate will form if mercuric chloride solution was not warm enough when mixed. In this case, begin again with the preparation of gold sublimate solution.

5% SODIUM THIOSULFATE (HYPO) SOLUTION

(See page 89)

STAINING PROCEDURE. Use acid clean glassware. Carry frozen sections on glass rod.

1. Rinse in distilled water, two changes.
2. Place sections flat in freshly prepared gold chloride-sublimate solution for 4 to 6 hours in the dark at room temperature.
3. Rinse in distilled water 5 minutes.
4. Sodium thiosulfate solution for 5 minutes.

Chapter 13

Methods For Bacteria, Fungi, And Inclusion Bodies

FITE'S METHOD FOR ACID FAST ORGANISMS

FIXATION. 10% buffered neutral formalin.

TECHNIQUE. Cut paraffin sections at 6 microns.

SOLUTIONS

XYLENE-PEANUT OIL SOLUTION

Peanut oil*	1 part
Xylene	2 parts

ZIEHL-NEELSEN CARBOL FUCHSIN SOLUTION

(See page 220)

1% SULFURIC ACID SOLUTION

(See page 102)

METHYLENE BLUE SOLUTIONS

(See page 218)

STAINING PROCEDURE. Use control slide.

1. Deparaffinize through two changes of xylene-peanut oil solution for 12 minutes each.
2. Drain, wipe off excess oil and blot to opacity. The residual oil helps prevent shrinkage and injury of section.
3. Zeihl-Neelsen carbol fuchsin solution for 30 minutes.
4. Wash in tap water for 3 minutes.
5. Differentiate slides individually with sulfuric acid solution until sections are faint pink, about 1 minute.
6. Wash in running water for 3 minutes.
7. Counterstain lightly with working methylene blue solution.
8. Rinse off excess methylene blue in tap water.
9. Blot and let stand for a few minutes to air dry thoroughly.
10. Dip slides in xylene before mounting.
11. Mount with Permount or Histoclad.

*Matheson, Coleman and Bell, Norwood, Ohio

Index

A

- Acid-fast organisms (*see* Bacteria)
- Actinomyces, stain for, 222
- Adhesives, section
 - albumin, dried, 28
 - albumin, egg, Mayer's, 28
 - celloidin, 29
 - gelatin, 28
 - gelatin-formalin, 29
- Adrenal gland, stain for, 107
- Alcoholic hyalin, stain for, 160
- Amoeba, stain for, 228
- Amyloid, stains for
 - Bennhold's (congo red), 153
 - Highman's (methyl violet), 156
 - Lieb's (crystal violet), 154
 - Sweat-Puchtler (sirius red), 154
 - Vassar-Culling (thioflavine T), 157
- Angle jig, 25
- Argentaffin granules, stains for
 - diazo method, 100
 - Fontana-Masson, 104
 - Schmorl's, 185
- Artifacts, 241 - 251
- Astrocytes, stain for, 189
- Attwood's Amniotic Fluid
 - embolism stain, 232
- Axis cylinders, stain for, 193
- Ayoub-Shklar Keratin and Prekeratin stain, 82

B

- Bacteria, stains for
 - Acid-fast organisms
 - Fite's, 217
 - Kinyoun's, 218
 - Truant's, 219
 - Wade's, 220
 - Ziehl-Neelsen, 220
 - Gram positive-Gram negative
 - Brown-Brenn, 222
 - Brown-Hopps, 224
 - MacCallum-Goodpasture, 225
 - Taylor's, 226
 - Baker's Phospholipids stain, 147
 - Basement membranes, stain for
 - Jones', 97
 - Lillie's, 72
 - Puchtler-Sweat, 73
 - Basophilic properties, restoration of, 44, 45
 - Bennhold's Amyloid stain, 153
 - Berg's Spermatozoa stain, 117
 - Best's Glycogen stain, 157
 - Bielschowsky's Axis Cylinder and Dendrite stain, 193

Bile

- canalliculi stain, 74
- pigment (bilirubin) stain, 174
- Bilirubin (bile), stain for, 174
- Biopsy processing, 18
- Bodian's Nerve Fiber stain, 195
- Bone
 - cortical, hand ground sections, 58
 - decalcification, 6 - 11
 - marrow processing, 18
 - marrow stain, 120
 - oral tissue processing, 60
 - jaw, 61
 - teeth, 60
 - large sections, processing, 59
 - temporal processing, 47
 - undecalcified, 57
- Bohmer's hematoxylin, 34
- Bosch's Negri Bodies stain, 207
- Bouin's fixative, 5
- Brown-Brenn Gram stain, 222
- Brown-Hopps Gram stain, 224
- Bullard's hematoxylin, 34

C

- Cain's Mitochondria stain, 129
- Calcium, stains for
 - Carr's, 174
 - Dahl's, 175
 - Kossa's, 176
 - Pizzolato's, 177
- Carbowax (*see* Polyethylene glycols)
- Carnoy's fixative, 5
- Carr's Calcium stain, 174
- Casper-Wolman Fluorescent Myelin figure stain, 202
- Castolite plastic solution, 57
- Celloidin methods
 - dry, 62
 - wet, 63
 - double embedding, 18
- Ceroid, stain for, 186
- Charcott Leyden crystals, stain for, 111
- Chelates decalcification agents, 9
- Chromaffin, stain for, 107
- Chitin, softening procedure, 11
- Cholesterol, stain for, 140
- Clarke's fixative, 5
- Collagen, stains for
 - Gomori's, 93
 - Mallory's, 75
 - Masson's, 94
 - Movat's, 95
 - Van Gieson's, 76
 - Weigert's, 80

Connective tissue, stains for
 Gomori's aldehyde fuchsin, 78
 Hart's (elastic fibers), 79
 Heidenhain's aniline blue, 86
 Lillie's allochrome, 72
 Mallory's (PTAH), 85
 collagen, 75
 Masson's trichrome, 94
 Movat's pentachrome, 95
 Pinkus acid orcein-giemsa, 77
 Puchtler-Sweat (basement membranes), 73
 Van Gieson's (collagen fibers), 76
 Weigert's (elastic fibers), 80
 Copper, stains for
 Perls', 184
 Uzman's, 178
 Cortical bone, ground sections of, 58
 Coverslips, removal of, 45, 46
 Cryptococcus, stain for, 161
 Cutting sections
 celloidin, 64
 frozen, 29, 40
 paraffin, 13
 plastic, 66
 Cytological buttons, processing of, 18

D

Dahl's Calcium stain, 175
 Dane's Prekeratin, Keratin and
 Mucin stain, 83
 Decalcification methods
 chelating agents, 9
 commercial, 8
 electrolytic, 9
 end point, 10
 formic acid-sodium citrate, 8
 nitric acid, 7, 8
 versenate, 9
 Decalcification, techniques for
 eye, 8
 large bones, 59
 teeth, 60
 temporal bones, 47
 Defano's Golgi Apparatus stain, 101
 DeGalantha's Urate Crystal stain, 187
 Dehydrating tissue, 12
 Delafield's hematoxylin, 34
 Diazo's Argentaffin Granule stain, 100
 Digestion procedures
 deoxyribonuclease, 135
 diastase, 171
 hyaluronidase, 171
 ribonuclease, 136
 sialidase, 172
 DNA Digestion, procedure for, 135
 Donovan Bodies, stain for, 238
 Double embedding, 18, 63

E

Ehrlich's hematoxylin, 35
 Einarson's Nissl Substance stain, 212

Elacin, stain for, 79
 Elastic fiber, stains for
 Gomori's aldehyde fuchsin, 78
 Hart's, 79
 Pinkus' acid orcein-giemsa, 77
 Weigert's, 80
 Electrolytic decalcification, 9
 Embedding methods
 carbowax, 19
 celloidin, 64
 double, 18, 63
 gelatin, 30
 general comments, 15
 multiple, 13
 paraffin, 13, 14
 plastic, 57
 Embolism, amniotic fluid stain, 232
 Endamoeba Histolytica, stain for, 228
 Eosin, 35, 36, 39
 Eosinophilic granules, stain for, 111
 Erythrocytes, stain for, 111
 Eye
 decalcification, 8, 53
 fixation, 53
 processing, 53
 sectioning, 54
 staining retinal vessels, 56
 trypsin digestion, 54

F

Fats and Lipids, stains for
 Fischler's (fatty acids), 142
 Gaucher's, 145
 Landing's, 145
 Mukherji's (unsaturated), 149
 Niemann-Pick, 145
 oil red O, 140
 osmium tetroxide (frozen sections), 143
 (paraffin sections), 143
 sudan black B, 145
 phospholipids (*see* Phospholipids)
 Seligman-Ashbel (active carbonyl lipids), 150
 Tay-Sachs, 145
 Fibrin, stains for
 Fraser-Lendrum, 81
 Mallory's (PTAH), 85
 Fibrinoid, stain for, 95
 Fischler's Fatty Acid Stain, 142
 Fite's Acid Fast Organism stain, 217
 Fixation, tissue, 1-6
 Fixatives
 alcohol, 2
 Bouin's, 5
 Carnoy's, 5
 Clarke's, 5
 formalin (10%), 1
 formalin-alcohol-acetic acid, 4
 formalin-ammonium bromide, 4
 formalin, buffered neutral, 3
 formalin-saline, 3
 formalin-sodium acetate, 3
 formol-calcium, 4

glacial acetic acid, 2
 glutaraldehyde, 6
 Helly's, 4
 mercuric chloride, 2
 Newcomer's, 5
 Orth's, 6
 paraformaldehyde, 6
 picric acid, 3
 potassium dichromate, 3
 Zenker's, 4
 Zenker's-Formalin (Helly's), 4
 Fixatives, characteristics of
 alcohol, 2
 formaldehyde, 1
 glacial acetic acid, 2
 mercuric chloride, 2
 picric acid, 3
 potassium dichromate, 3
 Formaldehyde gas, 1
 Fontana-Masson Silver stain for
 argentaffin granules, 104
 melanin, 104
 Formalin
 alcohol-acetic acid, 4
 ammonium bromide, 4
 buffered neutral, 3
 calcium, 4
 pigment, 43
 saline, 3
 sodium acetate, 3
 Zenker's, 4
 Formol-calcium, 4
 Fraser-Lendrum Fibrin stain, 81
 Frozen section techniques
 gelatin embedding, 30
 rush method, 40
 Fungi, stains for
 Brown-Brenn, 222
 Fite's, 217
 Gridley's, 229
 Grocott's (GMS), 230
 Mayer's Mucicarmine, 161
 McManus' (PAS), 158
 Pickett's (fluorescence), 232

G

Gaucher Lipid stain, 145
 Gelatin solutions, 31
 Giemsa stains
 AFIP method, 235
 May-Grunwald, 121
 Price's, 127
 Wolbach's, 119
 Glacial acetic acid, 2
 Glenner-Lillie Pituitary stain, 108
 Glial fibers (*see* Nerve cells)
 Glutaraldehyde fixative, 6
 Glycerin jelly (*see* chapter 9), 141
 Glycogen digestion, procedure for, 171
 Glycogen, stains for
 Best's carmine, 157
 McManus' (PAS), 158

Golgi apparatus, stain for, 101
 Gomori's stains for
 chromaffin, 107
 elastic fibers, 78
 iron, 179
 islet cells, pancreatic, 106
 reticulum, 87
 trichrome, 93
 Gridley's stain for
 endamoeba histolytica, 228
 fungi, 229
 Grocott's Fungi stain (GMS), 230
 Guard's Sex Chromatin stain, 136
 Guillory's Degenerating Nerve
 fiber stain, 190
 Gwyn-Heardman Motor End Plate stain, 213

H

Hall's Bilirubin (bile) stain, 174
 Harris' hematoxylin, 34
 Hart's Elastic Fiber stain, 79
 Heath's Pituitary stain, 109
 Heidenhain's Connective Tissue stain, 86
 Helly's fixative, 4, 5
 Hematoxylins
 Bohmer's, 34
 Bullard's, 34
 Delafield's, 34
 Ehrlich's, 35, 51
 Harris', 34
 Mayer's, 33, 36
 Weigert's, 35
 Hematoxylin and Eosin procedures
 Harris' method, 38
 for "Rush" frozen sections, 40
 Mayer's method, 36
 with phloxine-safran, 39
 Hemofuchsin, stain for, 122
 Hemoglobin, stains for
 Lison's, 123
 Puchtler, 124
 Puchtler-Sweat, 126
 Ralph's, 125
 Hemosiderin, stain for, 178
 Highman's Amyloid stain, 156
 Hirano-Zimmerman Nerve fiber stain, 198
 Holmes' Nerve Fiber stain, 196
 Holzer's Glial Fiber stain, 200
 Hukill-Putt Iron stain, 180
 Hyaluronic acid digestion,
 procedure for, 171

I

Impregnating tissue, 13
 Inclusion bodies, stains for
 Attwood's, 232
 Lendrum's 234
 Page-Green, 234
 Iodine solutions
 Gram's, 41
 Lugol's, 42

Iron, stains for
 Gomori's, 179
 Hukill-Putt, 180
 Johnson's (microincineration), 181
 Lillie's (ferric and ferrous iron), 182
 Mallory's, 183
 Perls', 184

J

Jaw bone, processing of, 61
 Johnson's stains for
 iron, 181
 metachromasia, 162
 Jones' Kidney stain, 97
 Juxtaglomerular granules, stain for, 102

K

Keratin and prekeratin, stains for
 Ayoub-Shklar, 82
 Dane's, 83
 Keratin softening, procedures for, 11
 Kidney, stain for, 97
 Kinyoun's Acid Fast Bacteria stain, 218
 Klinger-Ludwig Sex Chromatin stain, 138
 Klüver-Barrera Myelin stain, 203
 Kossa's Calcium stain, 176

L

Labeling slides for permanent filing, 46
 Landing's Lipid stain, 145
 Lapham's Myelin stain, 204
 Laqueur's Alcoholic Hyalin stain, 160
 Lepra Bacilli, stain for, 217
 Lendrum's Inclusion Bodies stain, 234
 Levaditi-Manovelian Spirochete stain, 238
 Lieb's Amyloid stain, 154
 Lillie's stain for
 connective tissue, 72
 ferric and ferrous iron, 182
 nucleic acids, 131
 Lipofuscin, stains for
 AFIP method, 186
 oil red O method, 186
 Lison's Hemoglobin stain, 123
 Luna's stains for
 charcott leyden crystals, 111
 eosinophilic granules, 111
 erythrocytes, 111
 mast cells, 114
 Luna-Ishak Bile Canaliculi stain, 74

M

MacCallum-Goodpasture Gram stain, 225
 McManus' Glycogen stain, 158
 Malarial Parasites, stains for
 Price's, 127
 Thomas', 129
 Malaria pigments, removal of, 43
 Maldonado's Pancreatic Islet Cell stain, 105
 Mallory bodies, stain for, 160

Mallory's stain, for
 CNS tissue (PTAH), 199
 collagen, 75
 hemofuchsin, 122
 phosphotungstic acid hematoxylin (PTAH), 85
 Manuel's Reticulum stain, 89
 Massiganani-Malferrari Negri Bodies stain, 208
 Masson's Trichrome Connective Tissue stain, 94
 Mast Cells, stains for
 Luna's, 114
 Unna's, 115
 Toren's, 116
 Maximow's Bone Marrow stain, 120
 May-Grunwald Giemsa stain, 121
 Mayer's stains
 hematoxylin, 33
 for cryptococcus, 161
 for mucin, 161
 Melanin pigment
 removal, 42
 stains for, 104, 185
 Menschik's Phospholipid stain, 152
 Menzies' stains for
 muscle striation, 84
 nucleic acids, 132
 Mercury precipitates, removal of, 41
 Metachromasia, stain for, 162
 Microincineration, procedure for, 181
 Microtome knives, care and use of, 21 - 25
 Mitochondria, stain for, 129
 Monroe-Frommer Pituitary stain, 112
 Motor end plates, stain for, 213
 Mounting media
 Apathy's, 156
 fluormount, 170
 glycerin jelly, 141
 XAM, 232
 Movat's Pentachrome stain, 95
 Mowry's Colloidal Iron stain, 167
 Mucin, stains for
 alcian blue, 163
 Dane's, 83
 Mayer's, 161
 McManus' (PAS), 158
 Mucosaccharides, stains for
 alcian blue, 163, 164
 aldehyde fuchsin, 165
 aldehyde fuchsin-alcian blue, 165
 colloidal iron modification, 167
 Dane's, 83
 diastase digestion method, 171
 hyaluronidase digestion method, 171
 miscellaneous polysaccharides, 172
 PAS-alcian blue, 168
 Saunder's, 169
 sialidase digestion method, 172
 Mukherji's Unsaturated Lipid stain, 149
 Multiple sections
 removal of, 68
 staining of, 69
 Muscle striation, stains for
 Mallory's (PTAH), 85
 Menzies' (cardiac), 84

Myelin, stains for
 Klüver-Barrera, 203
 Lapham's, 204
 Woelcke's, 206
 Myelin figures, stain for, 202

N

Nauta-Gygax Axon Terminal stain, 191
 Negri bodies, stains for
 Bosch's, 207
 Massiganani-Malferrari, 208
 Schleifstein's, 209
 Nerve cells and fibers, stains for
 astrocytes, 189
 axon terminals, 191
 axis cylinders and dendrites, 193
 central nervous system tissue
 aldehyde-thionin-PAS, 210
 PTAH, 199
 degenerating nerve fibers, 191
 glial fibers, 200, 204
 microglia, 201
 motor end plates, 213
 negri bodies, 207, 208, 209
 nerve cells, 196, 198, 203
 cell products, 212
 fibers, 195, 196, 198
 neural tissues, 215
 nissl substance, 212
 oligodendroglia, 201
 Newcomer's fixative, 5
 Niemann-Pick Lipid stain, 145
 Nissl substance, stain for, 212
 Nocardia filaments, stains for
 Brown-Brenn, 222
 Fite's, 217
 Grocott's (GMS), 230
 Nucleic acids, stains for
 Lillie's, 131
 Menzies', 132
 Spicer's, 133
 Taft's, 134

O

Oral tissue, processing of, 60
 Organs, large processing of, 59
 Orth's fixative, 6
 Osteoid material, stain for, 86

P

Page-Green Inclusion Bodies stain, 234
 Paget's cells, stain for, 165
 Pancreatic islet cells, stains for
 Glenner-Lillie, 108
 Gomori's, 106
 Heath's, 109
 Maldonado's, 105
 Monroe-Frommer, 112
 Wilson-Ezrin, 113
 Papanicolaou's stain, 70
 Paraformaldehyde, 6

Pearse's Phospholipid stain, 148

Penfield's Oligodendroglia-Microglia stain, 201

Perenyi's Decalcification method, 7

Perls' Iron stain, 184

Phloxine, 36

Phloxine-safran, 39

Phospholipids, stains for

Baker's, 147

Menschik's, 152

Pearse's, 148

pyridine extraction test, 148

Pickett's Fluorescence Fungi stain, 232

Pigment, removal of

formalin, 43

malaria, 43

melanin, 42

mercury, 41

Pinkerton's Rickettsia stain, 237

Pinkus' Acid Orcein-Giemsa stain, 77

Pituitary cells, stains for

Glenner-Lillie, 108

Heath's, 109

Mallory's, 75

Monroe-Frommer, 112

Wilson-Ezrin, 113

Pizzolato's Calcium Oxalate stain, 177

Plastic methods

castolite, 57

liquid film, 67

35 mm film, 65

multiple sections, removal of, 68

repairing slides, 68

Polychromatic stains

May-Grunwald Giemsa, 121

Price's Giemsa, 127

Siegel's, 131

Wolbach's Giemsa, 119

Polyethylene glycols (carbowax), 19

Price's Giemsa stain, 127

Processing

biopsies, 18

bone marrow, 18

brain tissue (table), 16

CNS tissue, 16

cytological buttons, 18

eye, 8, 53

jaw bones, 61

large bones, 59

soft tissue, 61

teeth, 60

temporal bones, 47

whole organs, 59

Puchtler-Sweat stains for

basement membrane, 73

hemoglobin, 126

hemosiderin, 126

Pyridine extraction test, 148

R

Ralph's Hemoglobin stain, 125

Ramon Y Cajal's Astrocyte stain, 189

Reducing substances, stain for, 185

INDEX

Reprocessing blocks, 15

Resealing blocks, 28

Reticulum, stain for
Gomori's (CNS Tissue), 87

Manuel's, 89

Snook's, 90

Wilder's, 92

Retinal vessels, demonstration of
staining (PAS), 56

trypsin digestion, 54

Rickettsia, stains for
giemsa, 235

Pinkerton's, 237

RNA digestion, procedure for, 136

S

Saunders Mucosaccharide stain, 169

Schleifstein's Negri Bodies stain, 209

Schmorl's (reducing substance) stain, 185

Schultz's Cholesterol stain, 140

Section adhesives (*see* Adhesives)

Sectioning hints, 25 - 28

Seligman-Ashbel Carbonyl stain, 150

Sevier-Munger Neural Tissue stain, 215

Sex chromatin, stains for

Guard's, 136

Klinger-Ludwig, 138

Sialic acid digestion, procedure for, 172

Siegel's Polychromatic stain, 131

Slides, repairing of, 68

Smith's Juxtaglomerular Granule stain, 102

Snook's Reticulum stain, 90

Soft tissue, processing of, 61

Spermatozoa, stain for, 117

Spicer's Nucleic Acid stain, 133

Spirochetes, stains for

Levaditi-Manovelian, 238

Warthin-Starry, 238

Staining, methods for

cellodin, 65

multiple, 69

Sweat-Puchtler Amyloid stain, 154

T

Taft's Nucleic Acid stain, 134

Taylor's Bacteria stain, 226

Tay-Sachs' Cells, 145

Temporal bone, processing of, 47

Thomas' Malaria Parasite stain, 129

Tissue processing schedules, 17

Toren's Mast cell stain, 116

Truant's Fluorescent Acid Fast stain, 219

Trypsin digestion for retinal vessels, 54

Tubercle bacilli (*see* Bacteria)

U

Undecalcified tissue, sectioning of

bone, 57

teeth, 57

Unna's Mast cell stain, 115

Urate crystals, stain for, 187

Uzman's Copper stain, 178

V

Van Gieson's Collagen Fiber stain, 76

Vassar-Culling Amyloid stain, 157

Versenate decalcification method, 9

Vogt's Nerve Cell products stain, 212

W

Wade's Acid Fast stain, 220

Warthin-Starry stains for

Donovan bodies, 238

spirochetes, 238

Weigert's stain

for elastic fibers, 80

hematoxylin, 35

Wilder's Reticulum stain, 92

Wilson-Ezrin Pituitary stain, 113

Woelcke's Myelin Sheath stain, 206

Wolbach's Giemsa stain for

bacteria, 119

rickettsia, 119

Z

Zenker's fixative, 4

Zenker-formalin (Helly's) fixative, 4

Ziehl-Neelsen Acid Fast stain, 220

The Causes and Consequences of Chromosomal Aberrations

Edited by
Ilan R. Kirsch, M.D.

Section Chief
N.C.I.—Navy Medical Oncology Branch
Attending Physician
Pediatric Branch
National Cancer Institute
Bethesda, Maryland



CRC Press
Boca Raton Ann Arbor London Tokyo

Chapter

1

Molecular Cytogenetics: Applications of Fluorescence Hybridization to Chromosomal Aberrations and Cancer Genetics

Yigong Xing and Jeanne Bentley Lawrence

*Department of Cell Biology
University of Massachusetts Medical Center
Worcester, Massachusetts*

INTRODUCTION

Advances in cytological hybridization technology have, over the last 20 years, progressed from a laborious and time-consuming approach to detect abundant nucleic acid sequences with low resolution, to an approach which allows quick and highly precise localization of as little as one molecule per cell. Using this technique, it is now possible to detect just a few kilobases of deleted or misplaced DNA anywhere within the genome. These improvements have important implications for human gene mapping as well as for investigations into the occurrence, causes, and consequences of chromosomal aberrations. In addition, while allowing for the determination of linear arrangements of genes on chromosomes, high-resolution *in situ* hybridization also makes possible detailed analysis of their three-dimensional organization and expression within the nucleus. In this chapter we will briefly review the development of this technology and highlight efforts from our laboratory as

well as others in this area. Various applications to chromosomal aberrations will be considered, with emphasis on cancer cytogenetics. Gene mapping techniques will be presented only briefly since this subject has been recently reviewed (Lawrence, 1990; McNeil et al., 1991; Lichter et al., 1991). Finally, recent developments in applications of fluorescence hybridization to interphase nuclear organization will be considered and discussed in relationship to the generation of specific chromosomal rearrangements.

Technical Development of *In Situ* Hybridization Technology

Early efforts in this field relied on autoradiographic detection of radioactive probes to detect abundant sequences, such as localization of DNA sequences in amplified polytene chromosomes or highly reiterated sequences on metaphase chromosomes (Gall and Pardue, 1969; Evans et al., 1974). Since then, statistical localization of single copy sequences based on autoradiographic grain distributions was described (Harper et al., 1981; Gerhard et al., 1981) and is still widely applied. However, the resolution of autoradiography is limited to large chromosomal segments, and the technique is extremely time consuming, generally requiring weeks for sufficient autoradiographic exposures. Moreover, this approach does not allow localization of a single sequence within a single cell, but requires analysis of grain distributions from 50 to 100 cells. Autoradiography does offer the advantage that cDNA sequences less than 1 kb can be used routinely for statistical localization; however, genomic clones containing repetitive sequences have not been used, presumably because of prohibitively high backgrounds.

Several laboratories have contributed to the development of innovative nonisotopic detection techniques to avoid the shortcomings inherent in autoradiographic methodologies (reviewed in Bauman et al., 1990; Lawrence, et al., 1990; Narayanswami and Hamkalo, 1991; Lichter et al., 1991; McNeil et al., 1991). During the 1980s, several approaches were described, including a method for direct labeling of fluorochromes to RNA probes (Bauman et al., 1981); the incorporation of biotinylated dUTP into DNA probes (Langer et al., 1981; Manning et al., 1975) detected by antibiotin antibodies after hybridization to amplified polytene sequences (Langer-Safer et al., 1982); the use of probes labeled with AAF (*N*-acetoxy-*N*-acetyl-2-aminofluorene) for detection of abundant sequences (Tchen et al., 1984); mercuration of probes (Dale et al., 1975; Hopman et al., 1986); and sulfonation (Verdlov et al., 1974) or direct attachment of enzymes (Renz and Kurz, 1984). Recently a system using digoxigenin-labeled nucleotides detected by antibodies carrying fluorescent or enzymatic tags has become popular (Boehringer Mannheim). Using improvements in the hybridization process (see below), most of these detectors are now known to be capable of detecting single-copy sequences, in some cases as small as 1 kb. Most recently, directly labeled nucleotides have become available (Boehringer Mannheim). Prelim-

inary data indicate that these are clearly effective for detecting centromere sequences (Gerdes and Lawrence, unpublished work); however, single-copy sensitivity has not yet been shown (although it most likely will be in the near future).

Labeled probes have most commonly been detected by fluorescent or enzymatic reporter molecules which recognize a modified probe. The enzymatic detection methods, such as horseradish peroxidase and alkaline phosphatase, require extra steps to produce a visible product; however, they have advantages over fluorescence in that the reaction can be prolonged in order to amplify signals, and the signals do not fade. Fluorescent tags, such as fluorescein or rhodamine, provide the highest resolution possible with the light microscope and can be adapted for multicolor labeling. Probes can also be detected with gold for electron microscopy (see Singer et al., 1989; reviewed in Narayanswami and Hamkalo, 1991).

Nonisotopic methods have been utilized for over a decade. However, due to apparent limitations in sensitivity and reproducibility their use was very restricted, but was successful in detecting highly abundant or amplified sequences (e.g., Wu and Davidson, 1981; Manuelidis et al., 1982). It is only in the last few years that the much greater potential of *in situ* probe technology has been realized, largely due to improvements in the total hybridization process, rather than in the detection systems themselves. Our contributions in this area relied on a rapid quantitative approach (Lawrence and Singer, 1985; Lawrence et al., 1988) devised to allow testing of a vast array of technical parameters, while controlling for the most commonly encountered internal variations. Detection of nucleic acids still within cytological materials is substantially more involved than when they are extracted and hybridized on filters. For analytical purposes, the steps of *in situ* hybridization are best divided into three main components: (1) *preservation* of target sequences in a well-preserved but accessible state, (2) *hybridization* of the probe to the target molecules with high efficiency and without substantial nonspecific adherence, and (3) *detection* of the probe with sufficient efficiency to give a detectable signal, with minimal nonspecific background. Failure of any one parameter in any of these components results in a lower signal-to-noise ratio and a loss of sensitivity. Hence, an analytical approach was adopted to allow simultaneous but separate quantitation of each component (Lawrence and Singer, 1985; Singer et al., 1987; Lawrence et al., 1988).

Our goal for DNA detection was to detect single-copy sequences with hybridization efficiency high enough to provide sister chromatid labeling and, hence, nonstatistical localization within individual cells. While many laboratories had developed different protocols for *in situ* hybridization, it was difficult to know *a priori* which parameters were unnecessary or even destructive, and which were essential for improving results. Using the rapid analytical approach by liquid scintillation counting (Lawrence and Singer,

1985), we were able to identify several key parameters which improved results reproducibly (reviewed in Lawrence, 1990; McNeil et al., 1991). Kinetic studies, for instance, revealed that hybridization of even complex sequences was complete within 3 to 4 h, and that longer hybridization times could cause decreased signal due to RNA degradation. Detection with avidin was found to be dramatically improved by simply changing the buffers used in staining. An extremely important parameter for eliminating the high backgrounds which had plagued the use of nonisotopic probes proved to be probe fragment size after labeling, which has unexpectedly been found to dramatically affect the nonspecific adherence for the probe to cytological material, and the iterative detection of individual molecules. When this hidden variable was controlled, it was then possible to change another key parameter, probe concentration. While the standard procedures called for low probe concentrations, these actually must be extremely high for single sequences ($\geq 5 \mu\text{g/ml}$), well above theoretical saturation. Other parameters which significantly influenced the quality of results (often by preserving DNA) are storing slides at -70°C and "hardening" by baking before denaturation; minimizing pretreatments prior to denaturation; omitting RNase A prior to hybridization; testing lots of formamide for neutral pH, correct melting point, and effectiveness for hybridization; monitoring of time, temperature, and pH during denaturation (Lawrence et al., 1988; reviewed in Johnson et al., in press). We found that autoclaving dextran sulfate further inhibits nonspecific sticking of probes. A variety of other steps were tested and found to be unnecessary, such as extensive rinses, proteinase digestion, and acetic anhydride.

Nonstatistical Sequence Detection

Combining the results of these analyses with elements of previous protocols (Harper et al., 1981; Gerhard et al., 1981; Langer et al., 1981), it was shown that it was possible to detect single sequences of a few kilobases by standard fluorescence microscopy using a one-step fluorescein-avidin detection of biotinated probes, without amplification or image-processing procedures (Lawrence et al., 1988). Figure 1A illustrates results, and Figure 2 outlines the protocol used. Perhaps the most critical aspect of this work was that the high hybridization efficiency and low background achieved allowed *nonstatistical* detection of single sequences, in greater than 90% of individual metaphase or interphase cells. The position of a sequence along the chromosome length became immediately obvious in just one metaphase due to the identical labeling of sister chromatids. Because of the extremely high signal-to-noise ratio it was possible to localize *single* sequences within *interphase* nuclei for the first time.

The power of this technology was initially exemplified for analysis of Epstein-Barr virus (EBV) sequences in human lymphoma cells (Lawrence et al., 1988) which revealed the then surprising degree of resolution attainable between closely spaced sequences within decondensed interphase nuclei. Not

Figure 1. (A) and a one-step visualized using a tetraploid cell and two derivative cell lines, L. Sciorra, D. New Jersey-R, and E. New Jersey-R, to cytogenetic analysis. The results are evidenced by the presence of signals which are observed in the chromosomes and are $\sim 5 \mu\text{m}$ apart. These signals are factor receptors and are less-condensed across the q12 and 17q11 bands separated by the C and D bands. (B) Tilghman and Johnson, 1990. With permission.




Figure 1. (A) Hybridization to an 18-kb target within the EBV genome, using biotin-labeled probes and a one-step fluorescein-avidin detection. Chromosomes are stained with propidium iodide and visualized using standard fluorescence microscopy. (B) Hybridization of a chromosome-7 library to a tetraploid cell line carrying a translocation involving this chromosome. Two normal chromosomes 7 and two derivative chromosomes (arrows) are observed. (Photograph contributed by K. Wydner and L. Sciorra, Department of Pediatrics, Diagnostic Genetics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.) (C) Hybridization of a chromosome-1 sequence to cytogenetic preparations of the Namalwa cell line, illustrating how a cytogenetic abnormality is evidenced by the nonidentical labeling of sister homologues. Note that three signals, rather than two, are observed within the interphase nucleus. The duplicated sequences are approximately 70 Mb apart and are ~5 μ m apart at interphase. (D) Simultaneous hybridization to *neu* (erB2) and nerve growth factor receptor cosmid clones which are closely linked and frequently resolvable along the length of less-condensed metaphase chromosomes. On more-condensed chromosomes, they may only be resolvable across the chromosome width. These sequences have been localized to separate bands (17q 11.2-q12 and 17q 21.3-q23), respectively and are ~10 cM apart (~10 Mb). (E and F) Dystrophin sequences separated by ~700 kb are clearly separated and resolvable in ~90% of interphase nuclei. (Figures 1A, C, and D from Lawrence, J. B., in *Genomic Analysis*, Vol. 1, *Genetic and Physical Mapping*, S. Tilghman and K. Davies, Eds., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1-38. Copyright 1990. With permission.)

Causes and Consequences of Chromosomal Aberrations

Section I




Figure 2. Methodology for hybridization and detection of specific DNA sequences in cytological preparations. (1) Cytogenetic preparations are made by standard techniques using hypotonic solution or methanol-acetic acid. Alternatively, intact cell samples are fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS). (2) Denature cellular DNA in 70% formamide, 2×SSC 70°C for 2 min, or treat samples with 0.2 M NaOH, 70% ethanol for 6 min. Then, dehydrate samples in 70, 95, and 100% ethanol briefly. For biotin- or digoxigenin-labeled probes, melt dry probe and unlabeled competitor DNA in 100% formamide for 10 min at 75°C. (3) Hybridize probes to samples at a final concentration of 2.5 to 5 µg/ml (for single-locus probes) in 50% formamide 2×SSC, 1% BSA, and 25% dextran sulfate, 37°C, overnight. (4) Detect hybridization with fluorochrome-linked avidin or antidigoxigenin in 4×SSC, 1% BSA, 37°C, 30 min. (5) Rinse samples in 50% formamide and 2×SSC, 2×SSC, 1×SSC, 30 min each. (6) Detect hybridization with fluorochrome-linked avidin or antidigoxigenin in 4×SSC, 1% BSA, 37°C, 30 min. (7) Rinse in 4×SSC, 4×SSC with 0.05% Triton, 4×SSC, 1×PBS, 15 min each. Further details of these protocols have been reviewed elsewhere (Lawrence, 1990; McNeil et al., 1991; Johnson et al., 1991b).

only were two closely integrated viral genomes detected and resolved, which had escaped previous autoradiographic analysis, but two sequences from either end of a single viral genome, spaced just 130 kb apart, could be resolved as two distinct, closely paired spots for each of the viral genomes (Lawrence et al., 1988). Using two different approaches, it was possible to

determine 1 and to esti phase order be surmised by 200 to hybridizatio intensity si second app rately and interpretation interphase distance be to gene maj mapping"

Gene Ma

An ob genes with genomes. 1 of this ap which hav autoradiogr currently fi amplificati cation of b probes of 1 today the r very impo could be u for detecti degent et a worked fo clones. (St Lichter et

For ge techniques and which help bridg the last fe 1990; Tras cence hyb of the limi and order 2 Mb (Lav

determine the orientation of the two genomes with respect to one another and to estimate the distance between them. First, from the observed interphase order of dim and bright signals and the distance between them, it could be surmised that the viral genomes were in reverse orientation and separated by 200 to 300 kb of cellular DNA. This was done using simultaneous hybridization of two probes of different sizes which produced different intensity signals and corresponded to opposite ends of the EBV genome. A second approach, whereby each of these two probes was hybridized separately and the average distance between them determined, confirmed this interpretation (reviewed in Lawrence, 1990). These results suggested that interphase analysis could be used to determine the order and approximate distance between tightly linked sequences, leading us to propose an approach to gene mapping by fluorescence hybridization termed "interphase chromatin mapping" (Lawrence et al., 1988).

Gene Mapping

An obvious and important application of the ability to detect single-copy genes with fluorescence is to contribute to mapping of the human and other genomes. The resolution of fluorescence, as well as the speed and efficiency of this approach, is far superior to previous autoradiographic techniques which have a limit of resolution on the order of 10^4 or 10^5 kb. While autoradiography has had some advantage in sensitivity over fluorescence, we currently find that fluorescent signals as small as 1 kb can be detected without amplification or image processing, particularly with digoxigenin. Amplification of biotinylated probes (Pinkel et al., 1986) can also be used to detect probes of this size (Fan et al., 1990). However, in much genomic mapping today the need is not to detect smaller probes, but larger ones. Hence, it was very important to show that genomic probes containing repetitive elements could be used. This was initially reported using competition with Cot-1 DNA for detection with peroxidase and interference reflection microscopy (Landegeent et al., 1987). Several laboratories then showed that a similar approach worked for fluorescence detection of single-copy phage, cosmid, or Yac clones (Staunton et al., 1989; Trask et al., 1989; Lawrence et al., 1990; Lichter et al., 1990).

For genome mapping, there is a need for alternative physical mapping techniques which provide resolution in the range of 1 to 2 Mb and below, and which allow evaluation of physical distance across a broad range, to help bridge the gap between lower- and higher-resolution techniques. Over the last few years, work from several laboratories (Lawrence et al., 1988, 1990; Trask et al., 1989, 1991; Lichter et al., 1990) has shown that fluorescence hybridization can provide such an approach. Rigorous characterization of the limits and versatility of this technique showed that the ability to resolve and order sequences on chromosomes generally does not extend below 1 to 2 Mb (Lawrence et al., 1990) (see Figure 1D). However, an important finding

was that resolution could be greatly enhanced by analyzing the distance between two sequences in the interphase nucleus, where the chromatin is much less condensed (Lawrence et al., 1988, 1990; Trask et al., 1989, 1991). As described above, this was initially based on the demonstration that one could detect two sequences within an EBV genome separated by 130 kb (Lawrence et al., 1988). Interphase distance was then shown to exhibit a strong correlation with DNA distance over the ranges examined, for both dhfr sequences in Chinese hamster (Trask et al., 1989) and for human dystrophin sequences in normal human cells (Lawrence et al., 1990), providing a needed approach for determining physical order. As illustrated in Figure 1 E and F, sequences within the dystrophin gene separated by 50 kb or more are readily resolved at interphase. Figure 3 schematically illustrates the type of results obtained by analyzing both interphase and metaphase cells, and the legend indicates the distances over which each approach is most successful for gene ordering.

Another major effort from several groups has involved the adaption of fluorescence hybridization with chromosome banding techniques (Figure 4), some of which allow probes and chromosomes to be identified simultaneously (Viegas-Pequignot et al., 1989; Lawrence et al., 1990; Fan et al., 1990; reviewed in McNeil et al., 1991). The details of various banding procedures as well as the strengths and limitations of both metaphase and interphase mapping have been extensively reviewed recently (Lawrence, 1990; Lichter et al., 1991; McNeil et al., 1991). Included in these is a discussion of dual or multicolor labeling techniques, and Figure 2 outlines our protocol for two-color detection, as detailed previously (Johnson et al., 1991a).

APPLICATIONS FOR ANALYSIS OF CYTOGENETIC ABERRATIONS

It is only recently that methodology for applying nonisotopic cytological hybridization for the analysis of cytogenetic aberrations has begun to realize its full potential. The speed, convenience, and precision of nonisotopic probe-labeling techniques make this technology applicable for diagnostic as well as research purposes. With the increased quality and reproducibility of results that can now be achieved, a new area of "molecular cytogenetics" has emerged, whereby standard karyotypic analysis is directly coupled with molecular biology. Until recently, the field of cytogenetics has been limited to the analysis of relatively gross chromosomal aberrations based on banding patterns. Standard karyotypic analysis, while allowing a survey of the complete chromosome complement, can only discern deviations in whole chromosomes or chromosome segments containing approximately 10 Mb or more of DNA. It is now possible to detect specific genetic defects 1000- to 10,000-fold smaller cytologically, and eventually it may become possible to detect

A. Lo

B. Tig
(50)

C. Tra

OC
DE
II
II

D. Trisc

Figure 3. In phase and n mosomes le from the sam but will still (C) Hybrid: cells. Solid normal cells hybridization chromosome metaphase n labeling will phase.




Figure 3. Hypothetical outcomes after hybridization of one or two single-copy probes to interphase and metaphase cells. (A) Loosely linked sequences will be resolvable along the chromosomes length and show only a distant pairing within interphase nuclei. (B) When sequences from the same chromosomal region become closer, they will no longer be resolvable at metaphase but will still be clearly visualized as closely paired signals within decondensed interphase nuclei. (C) Hybridization patterns for normal (left) and translocated (right) metaphase and interphase cells. Solid and open circles represent signals from two pairs of different chromosomes. In normal cells the interphase nucleus shows a widely dispersed variable distribution of four hybridization signals. In contrast, in cells carrying the translocation, the fusion of two different chromosomes consistently gives a pair of close solid and open signals in both interphase and metaphase nuclei. (D) In the case of trisomy, three chromosomes showing sister chromatid labeling will be seen in metaphase, and three hybridization signals will be visualized at interphase.




Figure 4. Localization of the PTP1B gene and p107 gene by fluorescence detection of *in situ* hybridization. (A) Diamidophenylindole staining of metaphase chromosomes from normal human lymphocytes. The large arrow points to the homologous pair of chromosome 20s. The small arrows indicate chromosome 19, distinguishable based on the staining pattern. (B) Fluorescence-avidin detection of hybridization with the biotin-labeled PTP1B genomic DNA probe. Both homologues of chromosome 20 label on both sister chromatids. (A and B from Brown-Schimer, S. et al., *Proc. Natl. Acad. Sci. U.S.A.* 87, 5148, 1990. With permission.) (C) Schematic representation of chromosome 20 with a summary of the PTP1B gene and p107 gene placement based on analysis of banded metaphase chromosomes and simultaneous localization of PTP1B gene and p107 gene on chromosome 20. (From Ewen et al., *Cell* 66:1155, 1991. With permission.)

even s
cytoge
resulti
appare
research
diagn
abnor
H
mere
appare
Figure
trisom
XX, a
chrom
aneopl
by sta
approa
essary
lymph
genetic
approa
trisom
with c
probes
unpubl
Cl
tion ar
strateg
charact
to be b
for a si
detecte
will be
the tra
Su
are rea
applica
deletio
zygosit
to disc
readily
presence
control
confide
dystrop

even smaller defects. In the hunt for specific disease genes, a molecular cytogenetic defect in the gene itself might be revealed, because any aberration resulting in nonidentical labeling of homologous chromosomes is readily apparent by this technique. Clearly, the technology has value for clinical research into the etiology of genetic disease, but the potential for clinical diagnostics is also strong. A few areas of potential application to cytogenetic abnormalities are summarized below.

Hybridization of chromosome libraries, chromosome-specific centromere probes, or even small single-copy sequences can all make readily apparent monosomies or trisomies of specific chromosomes (see, for example, Figure 1C). The most common clinical abnormalities in this category are trisomies 21, 13, and 18 and the sex chromosome abnormalities XO, XXX, XX, and XYY. With the use of a collection of several probes for the above chromosomes with multiple labels, it should be possible to screen for several aneuploidies at once. Although all of these aberrations are readily detectable by standard karyotypic analysis, an advantage of the *in situ* hybridization approach is that it can be done directly in interphase cells, making it unnecessary to culture cells, such as amniotic fluid cells or peripheral blood lymphocytes. Cremer et al. (1986) described the use of "interphase cytogenetics" for detecting trisomy 18, and other investigators have used this approach with chromosome libraries, for example, for demonstration of trisomy 21 (Lichter et al. 1988; Pinkel et al. 1988). Although initially done with chromosome libraries, the more discrete signals generated by smaller probes such as cosmids or cosmid sets are more easily enumerated (Lawrence, unpublished observations).

Chromosome libraries or specific repeats can also be used for the detection and characterization of translocations, as shown in Figure 1B. This strategy is applicable to the detection of specific translocations known to characterize particular types of cancers. In addition, translocations that appear to be balanced can be analyzed much more precisely using a battery of probes for a specific chromosomal region. Translocations may be even more readily detected at interphase using two probes known to flank the breakpoint, which will be detected unusually close together (on the same chromosome) when the translocation is present.

Submicroscopic deletions involving a few kilobases or more of DNA are readily apparent by *in situ* hybridization, which allows for many potential applications. Carrier detection is one example, since heterozygous gene deletions are difficult to identify by Southern blot analysis because heterozygosity is manifest only as the change in intensity of a band, often difficult to discern. With *in situ* hybridization, on the other hand, heterozygosity is readily apparent as the total absence of signal on one homologue. The presence of signal on the other homologue serves as an internal positive control. Because hybridization efficiency is high (>90%), deletions can be confidently identified by analysis of just a few cells. Duchenne's muscular dystrophy is an excellent example of how *in situ* deletion detection might be

useful. In this disease, the most common molecular defect has been identified as deletions of 6 kb or more in the dystrophin gene (Koenig et al., 1987). Once a specific deletion is identified in an affected male by filter hybridization with different probes, female family members can easily be screened for the same deletion using metaphase or interphase analysis (Lawrence et al., 1991). Affected individuals themselves might be screened with a small battery of probes for the most common deletions. As specific defects in inherited diseases are identified and characterized and the sensitivity and convenience of these techniques increases still further, the number of potential applications will grow. As considered below, one major area in which this may prove to be very important is in the diagnosis and study of cancer, which is essentially a genetic disease of somatic cells.

APPLICATIONS OF FLUORESCENCE HYBRIDIZATION TO CANCER GENETICS

Genetic changes are now well recognized to have a fundamental involvement in the complex process of cancer development for many, if not all, cancers. The specific genetic changes which contribute to cancer involve altered gene expression as a consequence of gene loss resulting from translocations or deletions, or smaller mutations such as point mutations. The ability of fluorescence *in situ* hybridization to provide more precise molecular cytogenetic analysis promises to make a significant contribution to the understanding and detection of genetic changes in cancer. Here we consider some of the ways in which *in situ* hybridization can be useful in investigating the etiology and diagnosis of cancer, after briefly reviewing some of the major types of genetic changes known to be involved.

The first consistent chromosome change in human cancer was the Philadelphia (or Ph¹) chromosome in chronic myelogenous leukemia (Nowell and Hungerford, 1960), which occurs as the result of a translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] (Rowley, 1973). There are now at least 70 recurring translocations that have been detected in human malignant cells (reviewed in Trent et al., 1989). For example, chromosome translocation breakpoints have been described in the mixed parotid gland tumors at 3q21 and 3q25; (Mark et al., 1980). A consistent deletion is another genetic factor frequently observed in human cancer, with deletion of a specific region correlated with a particular tumor tissue type. These rearrangements may be multiple and complex. For example, in human colorectal carcinomas, 5q, 17p, and 18q are all found to be altered in many tumors (Baker et al., 1989), and a putative tumor suppressor gene, Mcc, has been found at 5q21 (Kinzler et al., 1991).

In the progression of tumor formation, it has been found that either the activation of oncogenes or the inactivation of tumor suppressor genes, or

both, i
oncoge
ments
of the
located
man, 1
8q24,
1982),
often l
chromo
oncoge

Th
functio
whose
tumor.
suspec
develo
Rb ge
chrom
chrom
(Franc
Horow
have t
germ l
from t
in the
cell ca
et al.,

O
ties fo
of cap
the as
A key
affecte
consis
the es
volved
can be

Map

O
to can
which

both, play an important role. Proto-oncogenes, or the counterparts of viral oncogenes, have been found to be related to some chromosomal rearrangements recurrent in certain types of human cancers (Bishop, 1987). Mapping of these proto-oncogenes to human chromosomes revealed that many are located at the breakpoints implicated in different cancers (Heim and Mitelman, 1987). For example, the MYC proto-oncogene is found located at band 8q24, which is the breakpoint in Burkitt's lymphoma (Dalla-Favera et al., 1982), and the RAF1 oncogene has been mapped to band 3q25, which is often broken in mixed parotid gland tumors (Bonner et al., 1984). Hence, chromosomal changes may directly or indirectly induce the activation of oncogenes.

The tumor-suppressor genes are a group of genes which have important functions in the regulation of normal cell proliferation and development and whose presence in normal cells is required to prevent the emergence of a tumor. Loss of function of tumor suppressor genes has been found or is suspected in many different cancer types. A predominant example is the development of retinoblastoma, now known to involve loss of both allelic Rb genes mapped on the long arm of chromosome 13q14. Deletions of chromosome 13q are a consistent finding in patients with constitutional chromosome abnormalities who had a high incidence of retinoblastoma (Francke, 1976; Friend et al., 1986; Lee et al., 1988; Harbour et al., 1988; Horowitz et al., 1990). Individuals with the hereditary form of retinoblastoma have been found to have inherited the loss of one copy of the gene in the germ line, and then a somatic event inactivates the normal allele inherited from the other parent. It is now clear that Rb inactivation plays a key role in the pathogenesis of several commonly occurring tumors, including small cell carcinoma of the lung, bladder cancers, and breast carcinomas (T'ang et al., 1988; reviewed in Marshall, 1991).

One of several recent developments which have opened new opportunities for understanding the role of genetic factors in cancer is the expansion of capabilities for precise gene mapping. There are a number of reasons why the assigning of genes to chromosomes has received considerable attention. A key route to finding genetic factors involved in cancer is to identify genes affected as a consequence of specific chromosomal rearrangement that occur consistently in certain tumor types. Therefore, gene mapping will provide the essential information regarding the chromosomal location of genes involved in cancer and in the precise identification of the gene itself, which can be approached by several strategies.

Mapping Tumor Suppressor-Gene Candidates to Chromosomes

One approach in which *in situ* hybridization has potential to contribute to cancer genetics is to identify the chromosomal locus of a known gene which, based on its biochemical function, may be a putative tumor suppressor

or oncogene. It can then be determined if that locus correlates with known specific chromosomal changes implicated in tumors. Two examples in which our laboratory has applied this strategy, as part of collaborative efforts, involve genes encoding tyrosine phosphatases (Brown-Shimer et al., 1990) and p107, a protein with biochemical similarities to Rb (Dyson et al., 1989; Ewen et al., 1989; DeCaprio et al., 1989). This has resulted in the identification of two candidate genes possibly involved in myelogenous leukemia (Brown-Shimer et al., 1990; Ewen et al., 1991). This possibility must then be further investigated by analysis of whether those genes are specifically mutated in this cancer.

Biochemical studies have shown that increases in tyrosine phosphorylation by receptor tyrosine kinases lead to altered cell growth; hence, tyrosine kinases are recognized as important in the biochemistry of cancer. Similarly, loss or reduction in activity of a phosphotyrosyl phosphatase will also result in net increases in the phosphotyrosine content of cells and potentially lead to oncogenic transformation. *PTPG*, the gene for protein-tyrosine phosphatase γ has been mapped to chromosome region 3q21 and is found frequently deleted in renal cell carcinoma and lung carcinoma (LaForgia et al., 1991). Thus, the chromosomal location of tyrosine phosphatases has been of increasing interest (Brown-Shimer et al., 1990; LaForgia et al., 1991).

To determine if PTPase 1B mapped to any chromosomal site known to correlate with a specific cancer, a genomic clone was isolated and used as a probe for fluorescence hybridization to banded metaphase chromosomes. As illustrated in Figure 4, it was found that the human PTP1B gene is a single-copy gene located on chromosome 20q13.1-q13.2. This was of interest because the long arm of chromosome 20 was known to show deletions in or near this region in a significant fraction of cases with myeloid disorder (Davis et al., 1984), raising the possibility of involvement with myelogenous leukemia. Another putative tumor suppressor gene p107 was found to map to 20q (Ewen et al., 1991), possibly closer to the most consistent deletion in myelodysplastic disease (Yunis et al., 1988). The p107 protein has been of much interest as a potential tumor suppressor because it was found to share functional properties with the tumor suppressor product, RB, and binds to SV40 large T antigen and adenovirus E1A (DeCaprio et al., 1989; Dyson et al., 1989; Ewen et al., 1989). A cDNA clone for human p107 has been obtained, and its coding sequences map to chromosome 20q11.2. Using two-color hybridization it was directly shown that p107 is proximal to the centromere relative to PTPase 1B (Ewen, et al., 1991). Hence, these two genes provide good markers as well as candidate genes to better characterize the deletions of 20q in the tumors, which is often difficult with just banding procedures.

After mapping tumor suppressor genes to chromosomes from normal human samples, the next step is to identify if there is an allele loss in cancer cells. With clones of the possible tumor suppressor genes, *in situ* hybridization can be used to determine the number of copies of the gene in the

cance
of bot
chang
the pa
level.
and th
mutat
is us
such c
the ge
gene
detect
testing
tions i

Searc
Chro

A
is in :
mosor
or ye
mosor
label t
sequel
by ide
previo
be on
a sing
green,
ferenti
as bei
by *in* :
interpl
quenc
(~6 M

In
transla
knowl
from]
found
signal
Hence
that th

cancer cells compared with normal cells. In some cancers, the inactivation of both copies of the gene may be caused by different types of chromosomal changes. For example, in familial retinoblastoma, only a small fraction of the patients show germ-line loss of the first copy of the gene at the cytogenetic level. In most cases, no obvious cytogenetic abnormality can be detected and the inherited mutation is either a small deletion or even just a point mutation. However, the somatic event that causes the loss of the second copy is usually a large deletion, recombination, or total chromosome loss. For such changes, *in situ* hybridization will pick up the second, large deletion of the gene, but may not be able to detect the smaller abnormality in the first gene copy. In contrast, both copies of the gene in normal cells will be detected. This is essentially the same type of analysis for "heterozygosity" testing as described above, demonstrated for carriers of constitutional deletions in the dystrophin gene.

Search for Unknown Genes at a Known Chromosomal Breakpoint

Another strategy for which high-resolution *in situ* hybridization is useful is in searching for an unknown gene at the precise site of a known chromosomal breakpoint. This generally involves screening libraries of cosmids or yeast artificial chromosomes (YACs) from whole chromosomes or chromosome segments to find those clones closest to the breakpoint. Double-label fluorescence hybridization can be extremely valuable in searching for sequences near a deletion or breakpoint. The search generally would begin by identifying the two closest flanking markers for a specific deletion from previously mapped genes or RFLPs. Commonly, these flanking markers will be on the order of 5 to 10 Mb apart, an enormous distance when looking for a single gene. The two flanking markers can both be labeled in either red or green, and then probes for unknown sequences from that chromosome differentially labeled in the opposing color. The position of the clone of interest, as being between or outside of the two flanking markers can then be evaluated by *in situ* hybridization of the three probes simultaneously to metaphase and interphase cells. We have found this approach useful in searching for sequences near a translocation breakpoint flanked by markers 6 centimorgans (~6 Mb) apart (D. Shapiro and J. Lawrence, work in progress).

In searching for sequences at the breakpoint of chromosome 11q23 translocated in human acute leukemia, a series of YAC clones containing known genes on 11q23 were used as probes to hybridize to chromosomes from patients with acute leukemia (Rowley et al., 1990). What has been found is an intense labeling on the normal chromosome 11 and a less intense signal on the rearranged chromosomes as well as on the translocation partner. Hence, the YAC appeared to be split because of the translocation, indicating that the critical sequences at the breakpoint were within the YAC. This

greatly facilitates the identification of the gene, by limiting the area of the "walk" to identify coding sequences.

Molecular Cytogenetic Detection of Deletions, Translocations, or Other Chromosomal Rearrangements Associated with Specific Tumors

In the inherited forms of retinoblastoma, the absence of genetic material inherited from one of the parents can be detected by the loss of heterozygosity for markers flanking the locus. Since similar events uncovering recessive somatic mutations occur in the sporadic forms of retinoblastoma (Cavenee et al., 1983), the consistent loss of heterozygosity at specific loci in cancers may indicate deletion of tumor suppressor genes. As described above, heterozygous gene deletions may be difficult to identify by Southern blot analysis; however, with *in situ* hybridization submicroscopic deletions involving 1 to 2 kilobases or more of DNA are apparent as the total absence of signal on one homologue. The presence of signal on the other homologue serves as an internal positive control. Alternatively, fluorescence hybridization can be used to detect the amplification of specific sequences. This is evidenced as an increased number of signals for what is normally a single-locus probe, or, in some cases, increase intensity of specific signals. For example, it has been shown that *neu* oncogene is amplified in breast cancer (Salmon et al., 1989). Hence, the same technique that detects deletions should also be useful to identify gene amplification, which may be important for tumor prognosis.

To detect the specific translocation known to characterize particular types of cancers, chromosome libraries (see Figure 1B), specific repeats, or a group of probes for a specific chromosomal region can be used. Translocations may also be detected on metaphase chromosomes by comparing the location of probes which flank the site of the breakpoint on a given chromosome, as schematically represented in Figure 3C. For analysis of more easily obtained interphase cells, translocations may also be detected using two probes, one from each of the chromosomes involved in the translocation, which will be detected unusually close together (on the same chromosome) when the translocation is present (Figure 3C). In the case of bcr-abl fusion in chronic myelogenous leukemia, the fusion involves a translocation t(9;22)(q34;q11) to produce the characteristic Philadelphia (Ph¹) chromosome. The bcr probe and abl probe were labeled with two different fluorescence colors (red and green), and *in situ* hybridization was used for detection of the fusion in metaphase and interphase cells (Tkachuk et al., 1990). In contrast to the normal metaphase with abl and bcr at chromosomes 9 and 22, respectively, the bcr-abl fusion is shown by a very close two-color pair located in the Ph¹ chromosome. In interphase nuclei, one red and one green signal from chromosomes 9 and 22, respectively, were located randomly in normal interphase cells but in cells carrying the translocation appeared as a

red-green
the prese

Analysis

Non
and anal
of viral &
ogy of c
HPV (hi
cluding r
arising i
lieved th
was not
as well a
or prolif
1991). T
gration c
the detec
The fluo
integrate
sister ch
episomes
multiple
the chron
the locali
be impo
specific c

Nuclear

The
nology m
mosomes
organizati
understan
three-dim
While thi
may also
mosomal
mosomes
chromoso
reflect, ir

Whil
(reviewed

red-green doublet, with the separation between the two $<1 \mu\text{m}$, indicating the presence of the bcr-abl fusion gene.

Analysis of Viral Integration Sites

Nonisotopic *in situ* hybridization also makes possible the visualization and analysis of individual viral genomes within single cells. The introduction of viral genetic material into human chromosomes is implicated in the etiology of certain diseases, including different type of cancers. For example, HPV (human papilloma virus) is associated with several malignancies including nasopharyngeal carcinoma and Burkitt's and other B-cell lymphomas arising in immunosuppressed patients. While it was previously widely believed that integration of EBV occurred only in a few aberrant cell lines and was not important in the transformation process, using *in situ* hybridization as well as Southern blot analysis indicated that when EBV infects activated or proliferating B-cells it persists as a single integrated copy (Hurley et al., 1991). This finding then raises the interesting issue of to what extent integration could be playing a role in cancer formation. This finding, as well as the detection of episomal vs. integrated genomes, is illustrated in Figure 5. The fluorescence *in situ* hybridization can readily demonstrate single-copy integrated genomes in metaphase cells due to the identical labeling of the sister chromatids in the same chromosome. In contrast, cells containing episomes, which are always present in multiple copies, should demonstrate multiple single hybridization signals, apparently randomly associated with the chromosomes (Hurley et al., 1991). This enhanced ability to investigate the localization of viral genomes with respect to cellular genes is likely to be important for understanding the potential role of viral integration in specific chromosomal rearrangements or cancer.

Nuclear Organization

The new genre of more powerful nonisotopic *in situ* hybridization technology makes possible not only a more refined analysis of genes on chromosomes, but also opens the door for investigations into the higher-level organization of the interphase nucleus. Efforts to completely describe and understand complex genomes will ultimately require investigations into their three-dimensional organization in their functional state within the nucleus. While this has primarily a cell biological or developmental significance, it may also prove relevant to understanding the causes of some specific chromosomal aberrations. For instance, translocations between different chromosomes are not observed as random, but there is a propensity for certain chromosomes to be found recombined with one another, which could possibly reflect, in part, higher-level chromosome organization.

While much is understood about the nucleosome structure of chromatin (reviewed in Georgiev et al., 1981; and in Weisbrod, 1982), little is known




Figure 5. Detection of integrated and episomal viral genomes (A–C) Fluorescein hybridization signals using a *Bam*H1 W probe to the EBV genome, showing sister chromatid labeling of integrated EBV genomes. C shows that the same integration site is observed in identical positions in different cells of a chromosomal cell line. (D–G) The detection of episomal EBV genomes. (D) DNA hybridization within interphase nuclei of a cell line shown by Southern analysis to carry numerous episomal genomes. (E) DAPI DNA staining of nuclei in D. (F) Metaphase figures show numerous signals, but not in obvious sister chromatid labeling and in highly variable patterns. (G) DAPI of metaphase in F. (From Hurley, E. A. et al., *J. Virol.* 65, 1245, 1991. With permission.)

as yet about the higher-level organization of chromosomes and genes within the nucleus (Manuelidis and Borden, 1988; Hamkalo and Rattner, 1980). A three-dimensional order of chromatin within the interphase nucleus has been suggested by a variety of cytological observations (Comings, 1968, 1980; Manuelidis, 1985; Cremer et al., 1982; Hochstrasser and Sedat, 1987; Chung et al., 1990), some dating back over 100 years (Rabl, 1885). However, our understanding of nuclear organization has remained at a preliminary stage,

restrictive or nuclear reinforcement however tool which as their genome of the within rotated while orientation for a have localization localized no Barr orientation with re-unpublished that the is highly EBV specific particularly around 1985; P

Recently the nuclear reported type previously Ringertz whether poly(A) discrete these "tail-like" likely they these do genome (Carter years with tionally consistence function listed by consequences

Without not exten-

restricted primarily to investigations of satellite sequences (Manuelidis, 1984) or nuclear landmarks, such as the nucleolus. Such studies have clearly reinforced the cell type-specific higher-level organization of the genome; however, more refined analysis can now be done using a methodological tool which makes possible localization of specific single-copy genes as well as their cognate RNAs. Initial application of this tool revealed that the EBV genome is confined to an inner sphere of the nucleus representing only 50% of the volume, strongly indicating a sequence-specific, higher-level order within interphase chromatin (Lawrence et al., 1988). Even in randomly rotated suspension cells, the propensity for some sequences to be peripheral while others are confined to the nuclear interior has been readily observed for a host of other genes. For example, the *neu* oncogene has an interior localization in peripheral blood lymphocytes, whereas the dystrophin gene localizes at the extreme nuclear periphery, even in male cells where there is no Barr body (Lawrence et al., 1990). While there is clearly a nonrandom orientation to genes within nuclei, there appears to be substantial plasticity with regard to their precise localization (Lawrence, Coleman, and Xing, unpublished observations). This is also suggested by work demonstrating that the relative position of the two homologous chromosome 1 centromeres is highly variable (Van Dekken et al., 1990). The localization of expressed EBV sequences to the nuclear interior in Namalwa lymphoma cells is of particular interest in light of earlier suggestions that active chromatin localizes around the nuclear periphery (Hutchinson and Weintraub, 1985; Blobel, 1985; Puck et al., 1990).

Recent results provide strong evidence for the compartmentalization of the nucleoplasm into functional domains. For several years it has been reported that immunofluorescence for snRNP antigens of the RNA processing type produces clustered patterns within interphase nuclei (Fakan et al., 1986; Ringertz et al., 1986; Spector, 1990) although it had not been fully accepted whether this pattern is bona fide. Our laboratory has recently found that total poly(A) RNA, constituting 90% of mRNA, is localized within 10 to 20 discrete interphase domains (Carter et al., 1991). It was further shown that these "transcript domains" are enriched in snRNP proteins, making it highly likely that these are sites of mRNA processing. Other results indicate that these domains are nonrandomly positioned with respect to the underlying genome, raising the possibility that they are sites of mRNA transcription (Carter et al., 1991). A major goal of work in this area in the next several years will be to determine if active genes are clustered and, if so, if functionally related sequences or sequences from particular chromosomes are consistently localized together in specific cell types. The feasibility of a functional association of genes on different chromosomes is clearly established by the nucleolus, which represents the functional interaction of sequences on ten different chromosomes.

Work from several labs indicates that an individual chromosome does not extend throughout the entire nucleoplasm, but concentrates in a more

restricted space (Cremer et al., 1986; Pinkel et al., 1988; Lichter et al., 1988). It remains to be determined whether specific chromosomes are consistently positioned with respect to one another, which evidence indicates would occur in a cell type-specific manner. If so, this could in part explain why specific chromosomal pairs are most commonly translocated to one another in specific cell types. Another likely explanation for this is that the activation of oncogenes or deactivation of tumor suppressor genes which occurs as a consequence of a particular chromosomal rearrangement confers a selective advantage only in specific cell types. In this scenario, the frequency of different translocations is the same in all cells, but different ones are selected for in different cell types. It is perhaps likely that both of these mechanisms play a role in producing the higher cell type-specific distribution of chromosomal aberrations.

Another important feature of high-resolution *in situ* hybridization technology which has already provided insights into nuclear structure and has potential to contribute to investigations of genetic disease, is the ability to detect primary nuclear transcripts from expressed genes. Fluorescence visualization of specific viral RNAs has revealed very localized, often curvilinear "tracks" of nuclear RNAs up to 5 μ long (Lawrence et al., 1989, Figure 11B). This strongly suggests a highly structured nuclear interior in which RNA is not freely diffusing, and recent work indicates that this RNA may be tightly associated with a nonchromatin fibrillar matrix (Xing and Lawrence, 1991). Other potential applications for nuclear RNA detection may involve investigations into genetic disease; aberrant gene expression can result from a defect at one of several steps from gene to active protein. In the case of Duchenne's muscular dystrophy, a significant fraction of genetic defects in this gene (other than the ~60% known to be large deletions; Koenig et al., 1987) may result from defects in the enormous degree of processing that the dystrophin transcripts must undergo. Nonisotopic *in situ* hybridization provides a potential tool for detecting any chromosomal or genetic aberration that results in defective RNA processing.

ACKNOWLEDGMENTS

We thank Laurie Sullivan for her assistance in preparing and editing the manuscript. Our work described here represents the contributions of several people. Initial development of *in situ* technology was done in association with Robert Singer. Carol Villnave Johnson contributed to all phases of this development, and John McNeil was responsible for extending and adapting the technology for human genetics. We thank Karen Wydner and Leonard Sciorra for contributing the chromosome library detection of a translocation, and Cindy Beaudry for excellent secretarial assistance.

REF

Baker, J.M. and colo

Baumarizati, M.

Baumar Hemi hybr mosc

Bishop, Blobel, Bonner, (198 chro

Brown-Gree of th Acac

Carter, poly J. C.

Cavenec B.L. rece 305:

Chung, (199 pano

Coming Cremer, M. (hams

Cremer, Devi aberi DNA agno

Dale, R merc

Dalla-F: (198 trans

Davis, I mani Gene

REFERENCES

- Baker, S.J., Fearn, E.R., Nigro, J.M., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., Van Tuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., White, R. and Vogelstein, B. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science* 244:217.
- Bauman, J.G.J., Bayer, J.A. and Van Dekken, H. (1990) Fluorescent in-situ hybridization to detect cellular RNA by flow cytometry and confocal microscopy. *J. Microsc.* 157:73.
- Bauman, J.G.J., Wiegant, J., van Duijn, P., Lubsen, N.H., Sondermeijer, P.J.A., Hennig, W. and Kubli, E. (1981) Rapid and high resolution detection of in situ hybridization to polytene chromosomes using fluorochrome-labeled RNA. *Chromosoma* 84:1.
- Bishop, J.M. (1987) The molecular genetics of cancer. *Science* 235:305.
- Blobel, G. (1985) Gene gating: a hypothesis. *Proc. Natl. Acad. Sci. U.S.A.* 82:8527.
- Bonner, T., O'Brien, S.J., Nash, W.G., Rapp, U.R., Morton, C.C. and Leder, P. (1984) The human homologs of the raf(mil) oncogene are located on human chromosomes 3 and 4. *Science* 223:71.
- Brown-Shimer, S., Johnson, K.A., Lawrence, J.B., Johnson, C., Bruskin, A., Green, N.R. and Hill, D.E. (1990) Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. *Proc. Natl. Acad. Sci., U.S.A.* 87:5148.
- Carter, K.C., Taneja, K.L. and Lawrence, J.B. (1991) Discrete nuclear domains of poly(A) RNA and their relationship to the functional organization of the nucleus. *J. Cell Biol.* 115:1191.
- Cavenee, W.K., Dryja, T.P., Phillips, R.A., Benedict, W.F., Godbout, R., Gallie, B.L., Murphree, A.L., Strong, L.C. and White, R.L. (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature (London)* 305:779.
- Chung, H.-M.M., Shea, C., Fields, S., Taub, R.N., and Van der Ploeg, L.H.T. (1990) Architectural organization in the interphase nucleus of the protozoan *Trypanosoma brucei*: location of telomeres and mini-chromosomes. *EMBO J.* 9:2611.
- Comings, D. (1980) Arrangement of chromatin in the nucleus. *Hum. Genet.* 53:131.
- Cremer, T., Cremer, C., Schneider, T., Baumann, H., Hens, L., and Kirsch-Volders, M. (1982) Analysis of chromosome positions in the interphase nucleus of Chinese hamster cells by laser-UV-microirradiation experiments. *Hum. Genet.* 62:201.
- Cremer, T., Landegent, J., Bruckner, A., Scholl, H.P., Schardin, M., Hager, H.D., Devilee, P., Pearson, P. and Van der Ploeg, M. (1986) Detection of chromosome aberrations in the human interphase nucleus by visualization of specific target DNAs with radioactive and non-radioactive in situ hybridization techniques: diagnosis of trisomy 18 with probe L1.84. *Hum. Genet.* 74:346.
- Dale, R.M.K., Martin, E., Livingstone, D.C. and Ward, D.C. (1975) Direct covalent mercuration of nucleotides and polynucleotides. *Biochemistry* 14:2447.
- Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. and Croce, C.M. (1982) Human c-myc onc gene is located on the region of chromosome 8 that translocated in Burkitt lymphoma cells. *Proc. Natl. Acad. Sci. U.S.A.* 79:7824.
- Davis, M.P., DeWald, G.W., Pierre, R.V. and Hoagland, H.C. (1984) Hematologic manifestation associated with deletion of the long arm of chromosome 20. *Cancer Genet. Cytogenet.* 12:63.

- DeCaprio, J.A., Ludlow, J.W., Lynch, D., Furukawa, Y., Griffin, J., Piwonica-Worms, H., Huang, C.-M. and Livingston, D.M. (1989) The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. *Cell* 58:1085.
- Dyson, N., Buchkovich, K., Whyte, P. and Harlow, E. (1989) The cellular 107 K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. *Cell* 58:249.
- Evans, H., Buckland, R. and Pardue, M.L. (1974) Location of the genes coding for 18S and 28S ribosomal RNA in the human genome. *Chromosoma* 48:405.
- Ewen, M.E., Ludlow, J.W., Marsilio, E., DeCaprio, J.A., Millikan, R.C., Cheng, S., Paucha, E. and Livingston, D.M. (1989) An N-terminal transformation-governing sequence of SV40 large T antigen contributes to binding of both p110RB and a second cellular protein, p120. *Cell* 58:257.
- Ewen, M.E., Xing, Y., Lawrence, J.B. and Livingston, D.M. (1991) Molecular cloning. Chromosomal mapping and expression of the cDNA for p107 a retinoblastoma gene product-related protein. *Cell* 66:1155.
- Fakan, S., Leser, G. and Martin, T.E. (1986) Immunoelectron microscope visualization of nuclear ribonucleoprotein antigens within spread transcription complexes. *J. Cell Biol.* 103:1153.
- Fan, Y.S., Davis, L.M. and Shows, T.B. (1990) Mapping small DNA sequences by fluorescence in situ hybridization directly on banded metaphase chromosomes. *Proc. Natl. Acad. Sci. U.S.A.* 87:6223.
- Francke, U. 1976. Retinoblastoma and chromosome 13. *Cytogenet. Cell Genet.* 16:131.
- Friend, S.H., Bernard, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M., Albert, D.M. and Drja, T.P. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma. *Nature (London)* 323:643.
- Gall, J.G. and Pardue, M.L. (1969) Formation and detection of RNA-DNA hybrid molecules in cytological preparations. *Proc. Natl. Acad. Sci. U.S.A.* 63:378.
- Georgiev, G.P., Bakayev, V.V., Nedospason, S.A., Razir, S.V. and Mantieve, V.L. (1981) Studies on structure and function of chromatin. *Mol. Cell Biochem.* 40:29.
- Gerhard, D.S., Kawasaki, E.S., Carter, F., Bancroft, F.C. and Szabo, P. (1981) Localization of a unique gene by direct hybridization in situ. *Proc. Natl. Acad. Sci. U.S.A.* 78:3755.
- Hankalo, B.A. and Rattner, J.B. (1980) Folding up genes on chromosomes. *Q. Rev. Biol.* 55:409.
- Harbour, J.W., Lai, S.L., Whang-Peng, J., Gazdar, A., Minna, J.D. and Kaye, F.J. (1988) Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. *Science* 241:353.
- Harper, M.E., Ullrich A. and Saunders, G.R. (1981) Localization of the human insulin gene to the distal end of the short arm of chromosome 11. *Proc. Natl. Acad. Sci. U.S.A.* 78:4458.
- Heim, S. and Mitelman, F. (1987) Nineteen of 26 cellular oncogenes precisely located in the human genome map to one of the 83 bands involved in primary cancer-specific rearrangements. *Hum. Genet.* 75:70.
- Hochstrasser, M. and Sedat, J.W. (1987) Three-dimensional organization of *Drosophila melanogaster* interphase nuclei. II. Chromosome spatial organization and gene regulation. *J. Cell Biol.* 104:1471.

- Hopman, A.H., Wiegant, J., Tesser, G.I. and van Duijn, P. (1986) A nonradioactive method based on mercurated nucleic acid probes and sulphydryl-hapten ligands. *Nucleic Acids Res.* 14:6471.
- Horowitz, J.M., Park, S.-H., Bogenmann, E., Cheng, J.-C., Yandell, D.W., Kaye, F.J., Minna, J.D., Dryja, T.P. and Weinberg, R.A. (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. *Proc. Natl. Acad. Sci. U.S.A.* 87:2275.
- Hurley, E.A., Agger, S., McNeil, J.A., Lawrence, J.B., Calendar, A., Lenoir, G. and Thorley-Lawson, D.A. (1991) Epstein-Barr virus integrates when it infects B cell lines. *J. Virol.* 65:1245.
- Hutchinson, N. and Weintraub, H. (1985) Localization of DNase I-sensitive sequences to specific regions of interphase nuclei. *Cell* 43:471.
- Johnson, C.V., McNeil, J.A., Carter, K.C. and Lawrence, J.B. (1991a) A simple, rapid technique for precise mapping of multiple sequences in two colors using a single optical filter set. *GATA* 8:75.
- Johnson, C.A., Singer, R.H. and Lawrence, J.B. (1991b) Fluorescent detection of nuclear RNA and DNA: Implications for genome organization. *Methods in Cell Biology* 35:73.
- Kinzler, K. W., Nilbert, M.C., Vogelstein, B., Bryan, T.M., Levy, D.B., Smith, K.J., Preisinger, A.C., Hamilton, S.R., Hedge, P. and Markham, A. (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. *Science* 251:1366.
- Koenig, M., Hoffman, E.P., Bertesom, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. *Cell* 50:509.
- LaForgia, S., Morse, B., Levy, B., Levy, J., Barnea, G., Cannizzaro, L.A., Li, F., Nowell, P.C., Boghosian-Sell, L., Glick, J., Weston, A., Harris, C.C., Drabkin, H., Patterson, D., Croce, C.M., Schlessinger, J. and Huebner, K. (1991) Receptor protein-tyrosine phosphatase λ is a candidate tumor suppressor gene at human chromosome region 3p21. *Proc. Natl. Acad. Sci. U.S.A.* 88:5036-5040.
- Landegent, J.E., Jansen in de Wal, N., Dirks, R.H., Baas, F., and van der Ploeg, M. (1987) Use of whole cosmid cloned genomic sequences for chromosomal localization by non-radioactive *in situ* hybridization. *Hum. Genet.* 77:366.
- Langer, P.R., Waldrop, A.A. and Ward, D.C. (1981) Enzymatic synthesis of biotin-labeled polynucleotides: Novel nucleic acid affinity probes. *Proc. Natl. Acad. Sci. U.S.A.* 78:6633.
- Langer-Safer, P.R., Levine, M. and Ward, D.C. (1982) Immunological method for mapping genes on *Drosophila* polytene chromosomes. *Proc. Natl. Acad. Sci. U.S.A.* 79:4381.
- Lawrence, J.B. (1990) A fluorescence *in situ* hybridization approach for gene mapping and the study of nuclear organization. *Genome Analysis, Volume 1: Genetic and Physical Mapping*. S. Tilghman and K. Davies (Eds.), Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1-38.
- Lawrence, J.B., Caskey, T. and McNeil, J.A. (1991) Carrier detection for Duchenne's muscular dystrophy by *in situ* hybridization. Short report, *Advances in Gene Technology: The Molecular Biology of Human Genetic Disease*. (Symposium Publication of Miami Symposium, Jan. 27 to Feb. 1, 1991.)

- Lawrence, J.B. and Singer, R.H. (1985) Quantitative analysis of in situ hybridization methods for the detection of actin gene expression. *Nucleic Acids Res.* 13:1777.
- Lawrence, J.B., Singer, R.H. and Marselle, L.M. (1989) Highly localized tracks of specific transcripts within interphase nuclei visualized by in situ hybridization. *Cell* 57:493.
- Lawrence, J.B., Singer, R.H. and McNeil, J.A. (1990) Interphase and metaphase resolution of different distances within the human dystrophin gene. *Science* 249:928.
- Lawrence, J.B., Villnave, C.A. and Singer, R.H. (1988) Sensitive high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. *Cell* 52:51.
- Lee, E.Y.-H., To, H., Shew, J.-Y., Bookstein, R., Scully, P. and Lee, W.-H. (1988) Inactivation of the retinoblastoma susceptibility gene: cloning, identification, and sequence. *Science* 241:218.
- Lichter, P., Boyle, A.L., Cremer, T. and Ward, D.C. (1991) Analysis of genes and chromosomes by non-isotopic in situ hybridization. *Genet. Anal. Tech. Appl.* 8:24.
- Lichter, P.T., Cremer, T., Tang, C.-J.C., Watkins, P.C., Manuelidis, L. and Ward, D.C. (1988) Rapid detection of human chromosome 21 aberrations by in situ hybridization. *Proc. Natl. Acad. Sci. U.S.A.* 85:9664.
- Lichter, P., Tang, C.C., Call, K., Hermanson, G., Evans, G., Housman, D. and Ward, D.C. (1990) High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. *Science* 247:64.
- Manning, J.E., Hershey, N.D., Broker, T.R., Pellegrini, M., Mitchell, H.K. and Davidson, N. (1975) A new method of in situ hybridization. *Chromosoma* 53:107.
- Manuelidis, L. (1984) Different central nervous system cell types display distinct and non-random arrangements of satellite DNA sequences. *Proc. Natl. Acad. Sci. U.S.A.* 81:3123.
- Manuelidis, L. (1985) Individual interphase chromosome domains revealed by in situ hybridization. *Hum. Genet.* 71:288.
- Manuelidis, L., Langer-Safer, P. and Ward, D.C. (1982) High resolution mapping of satellite DNA using biotin-labeled DNA probes. *J. Cell Biol.* 95:619.
- Manuelidis, L. and Borden, J. (1988) Reproducible compartmentalization of individual chromosome domains in human CNS cells revealed by in situ hybridization and three-dimensional reconstruction. *Chromosoma* 96:397.
- Mark, J., Dahlfors, R., Ekedahl, C. and Stenman, G. (1980) The mixed salivary gland tumor — A normally benign human neoplasm frequently showing specific chromosomal abnormalities. *Cancer Genet. Cytogenet.* 2:231.
- Marshall, C.J. (1991) Tumor suppressor genes. *Cell* 64:313.
- McNeil, J.A., Johnson, C.V., Carter, K.C., Singer, R.H. and Lawrence, J.B. (1991) Localizing DNA and RNA within nuclei and chromosomes. *Genet. Anal. Tech. Appl.* 8:41.
- Narayanswami, S. and Hamkalo, B. (1991) DNA sequence mapping using electron microscopy. *Genet. Anal. Tech. Appl.* 8:14.
- Nowell, P.C. and Hungerford, D.A. (1960) A minute chromosome in human granulocytic leukemia. *Science* 132:1497.
- Pinkel, D., Landegent, J., Collins, C., Fuscoe, J., Seagraves, R., Lucas, J. and Gray, J. (1988) Fluorescence in situ hybridization with human chromosome-specific libraries: Detection of trisomy 21 and translocations of chromosome 4. *Proc. Natl. Acad. Sci. U.S.A.* 85:9138.
- Pinkel, D
high-se
Puck, T.J
cells. S
Rabl, C.
Renz, M.
Acids 1
Ringertz,
G.C. (the spa
4:11.
Rowley,
genous
243:29
Rowley,
S., Ta
Domer
human
tion br
87:935
Salmon,
Levin,
proto-
Singer, F
of cyt
hybrid
Singer, I
sensiti
In Situ
Eberw.
Spector,
tion of
87:147
Staunton
Dustin
phatid:
to chro
T'Ang, A
Struct
Scienc
Tchen, P
acids :
Sci. U
Tkachuk
Suryai
Detect
zation

- Pinkel, D., Straume, T. and Gray, J.W. (1986) Cytogenetic analysis using quantitative high-sensitivity, fluorescence hybridization. *Proc. Natl. Acad. Sci. U.S.A.* 83:2934.
- Puck, T.T., Krystosek, A. and Chan, D.C. (1990) Genome regulation in mammalian cells. *Somat. Cell Mol. Genet.* 16:257.
- Rabl, C. (1885) Über Zelltheilung. *Morphol. Jahrb.* 10:214.
- Renz, M. and Kurz, C. (1984) A colorimetric method for DNA hybridization. *Nucleic Acids Res.* 12:3435.
- Ringertz, N., Hadlaczky, H.H., Hallman, H., Nyman, U., Pettersson, I. and Sharp, G.C. (1986) Computer analysis of the distribution of nuclear antigens: studies on the spatial and functional organization of the interphase nucleus. *J. Cell Sci. Suppl.* 4:11.
- Rowley, J.D. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinicine fluorescence and Giemsa staining. *Nature* 243:290.
- Rowley, J.D., Diaz, M.O., Espinosa, R., III, Patel, Y.D., Van Melle, E., Ziemin, S., Taillon-Miller, P., Lichter, P., Evans, G.A., Kersey, J.H., Ward, D.C., Domer, P.H. and LeBeau, M.M. (1990) Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome. *Proc. Natl. Acad. Sci. U.S.A.* 87:9358.
- Salmon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 244:707.
- Singer, R.H., Langevin, G.L. and Lawrence J.B. (1989) Ultrastructural visualization of cytoskeletal mRNAs and their associated proteins using double-label *in situ* hybridization. *J. Cell Biol.* 108:2343.
- Singer, R.H., Lawrence, J.B., and Rashtchian, R.N. (1987) Towards a rapid and sensitive *in situ* hybridization methodology using isotopic and non-isotopic probes. *In Situ Hybridization: Application to the Central Nervous System* K. Valentino, J. Eberwine and J. Barchas (Eds.) Oxford University Press, New York, 71.
- Spector, D.L. (1990) Higher order nuclear organization: three-dimensional distribution of small nuclear ribonucleoprotein particles. *Proc. Natl. Acad. Sci. U.S.A.* 87:147.
- Staunton, D.E., Fisher, R., LeBeau, M., Lawrence, J.B., Burton, D., Franke, U., Dustin, M. and Thorley-Lawson, D.A. (1989) Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor is related to LFA-3 and Ox-45, and maps to chromosome 1q 21-24. *J. Exp. Med.* 169:1087.
- T'Ang, A., Varely, J.M., Chakraborty, S., Murphree, A.L. and Fung, T.K. (1988) Structural rearrangement of the retinoblastoma gene in human breast carcinoma. *Science* 242:263.
- Tchen, P., Fuchs, R.P.P., Sage, E. and Leng, M. (1984) Chemically modified nucleic acids as immunodetectable probes in hybridization experiments. *Proc. Natl. Acad. Sci. U.S.A.* 81:3466.
- Tkachuk, D.C., Westbrook, C.A., Andreeff, M., Donlon, T.A., Cleary, M.L., Suryanarayanan, K., Homge, M., Redner, A., Gray, J. and Pinkel, D. (1990) Detection of bcl-abl fusion in chronic myelogenous leukemia by *in situ* hybridization. *Science* 250:559.

- Trask, B., Pinkel, D. and van den Engh, G. (1989) The proximity of DNA sequences in interphase cell nuclei is correlated to genomic distance and permits ordering of cosmids spanning 250 kilobase pairs. *Genomics* 5:710.
- Trask, B.J., Massa, H., Kenrick, S., and Gitschier, J. (1991) Mapping of human chromosome xq28 by 2-color fluorescence in situ hybridization of DNA sequences to interphase cell nuclei. *Am. J. Hum. Genet.* 48:1.
- Trent, J.M., Kaneko, Y. and Mitelman, F. (1989) Human gene mapping 10: report of the committee on structural chromosome changes in neoplasia. *Cytogenet. Cell Genet.* 51:533.
- Van Dekken, H., Van Rotterdam, A., Jonker, R.R., Van der Voort, H.T.M., Brakenhoff, G.J. and Bauman, J.G.J. (1990) Spatial topography of a pericentromeric region (1Q12) in hemopoietic cells studied by in situ hybridization and confocal microscopy. *Cytometry* 11:570.
- Verdlov, E., Monastyrskaya, G.S., Guskova, L.I., Levitan, T.L., Sheichenko, V.I. and Budowsky, E. (1974) Modification of cytidine residues with a bisulfite-O-methylhydroxylamine mixture. *Biochim. Biophys. Acta* 340:153.
- Viegas-Pequignot, E., Li, Z., Dutrillaux, B., Apion, F. and Parkin, D. (1989) Assignment of human desmin gene to band 2q35 by non-radioactive in situ hybridization. *Hum. Genet.* 83:33.
- Weisbrod, S. (1982) Active chromatin. *Nature (London)* 297:289.
- Wu, M. and Davidson, N. (1981) Transmission electron microscopic method for gene mapping on polytene chromosomes by in situ hybridization. *Proc. Natl. Acad. Sci. U.S.A.* 78, 7059.
- Xing, Y., and Lawrence, J.B. (1991) Preservation of specific RNA distribution within the chromatin-depleted nuclear substructure demonstrated by in situ hybridization coupled with biochemical fractionation. *J. Cell Biol.* 112:1055.
- Yunis, J.J., Lobell, M., Abnesen, M.A., Oken, M.M., Mayer, M.G., Rydell, R.E. and Brunning, R.D. (1988) Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. *Br. J. Haematol.* 68:189.

IN

imp
in g
wit
spn
tary
of
chr
ana
neo
det
also
pre
link
wit

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.